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Osteoporosis is a degenerative bone disease characterized by low bone 
mineral density (BMD) and increased risk of fracture associated with higher 
morbidity and mortality. Current treatments for osteoporosis included 
antiresorptives that reduce bone turnover and halt the bone loss and anabolics 
that enhance bone turnover and encourage new bone formation. The majority 
of osteoporosis therapies are antiresorptives and there is only one type of 
anabolic therapy based on parathyroid hormone (PTH) analogue. Current 
available treatments have their limitations and there is a medical need for new 
anabolic bone treatment. 
Anti-sclerostin therapy is currently being developed as a bone anabolic 
treatment for degenerative bone diseases. Sclerostin is a protein produced by 
osteocytes which inhibits bone formation. Monoclonal antibodies (mAbs) that 
target and disrupt the sclerostin actions demonstrated increase in bone 
formation and BMD in preclinical experiments and clinical trials. The 
increased anabolic bone activities were not associated with elevated bone 
resorption, unlike PTH based therapy. This novel therapeutic mechanism is a 
promising new treatment option for osteoporosis. 
In the first part of this report, we built a population pharmacokinetic-
pharmacodynamics (PK-PD) model investigating the exposure and efficacy of 
blosozumab. Blosozumab is a humanized mAb against sclerostin tested 
clinically for the treatment of osteoporosis by Eli Lilly and Company.  The 
population PK of blosozumab was characterized by a two-compartment model 
with first-order absorption and both linear and saturable clearance (CL). Body 
weight was found to influence volume of distribution and saturable CL. The 
population PK-PD model was an indirect response model linked to a 
 VIII 
 
hypothetical target engagement module which drives up production rate of 
BMD.   
In the second part of this report, we assembled publicly available 
information of anti-sclerostin clinical trials and built an integrated systems 
biology bone remodeling model with the actions of sclerostin on osteoblast 
and osteoclast regulations. A target-mediated drug disposition model was first 
developed based on the reported PK and total sclerostin level to quantify the 
level of target engagement and predict the unbound sclerostin profiles. The 
regulatory actions of sclerostin on osteoblast and osteoclast were added to a 
bone remodeling model as described by Lemaire et al., 2004. Sclerostin 
regulate bone formation by enhancing apoptosis and repressing the maturation 
of active osteoblasts as well as activate osteoclast maturation. The osteoblast 
and osteoclast were then linked to the BMD formation and destruction rates to 
describe the lumbar spine and total hip BMD response.  
 Both models were compared and used to predict and optimize dose 
regimens for future clinical trials. The systems biology model was used to 
predict clinical efficacies of a wide range of dose regimens and generate 
hypothesis of sclerostin regulation of bone formation. The population PK-PD 
model was used to quantify variability, identify potential covariates, refine the 
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1.1. Bone Morphology and Functions 
The human bone is a dynamic system that performs several important 
roles to ensure the proper operations of the human body. It performs structural, 
mechanical and metabolic tasks. The human bones make up the skeletal 
framework that gives structural support to the body and protect the internal 
organs from external forces. To perform these mechanical tasks, a strong and 
lightweight structural framework is essential. The bone is a living tissue that 
continuously undergoes dynamic remodeling process to repair the micro-
fractures sustained from the daily mechanical stresses
1
.  It was discovered that 
mechanical loading stimulates the bone formation activities, whereas lack of 
physical exercise causes bone loss. Bone strength and bone strain play a 
balancing act to govern the bone resorption and formation rate in a process 
known as mechanostat
2
. Bone strength is dependent on bone mass and the 
architectural construction.  Although the effect of three-dimensional bone 
construction on bone strength is unclear, increasing bone mass will improve 
bone strength. Bone strain, on the other hand, measures the elastic deformation 
of the bone due to mechanical loading. There is a natural feedback between 
these two factors; where high bone mass discourages active bone formation 
whereas bone strain is necessary to maintain the bone integrity
3
. Additionally, 
the bone is also a metabolically active site where hematopoiesis primarily 




Although the human bone can come in different shapes and sizes, the 
general gross anatomy is similar and is composed of multiple layers. 
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Periosteum is a membranous layer that encases the outer surface of the bone. 
Beneath the periosteum is a dense cortical bone layer surrounding an inner, 
more matrix-like, porous trabecular bone. The endosteum separates the 
cortical bone and the trabecular bone. The cortical bone consists of multiple 
concentric structures called an osteon. The osteons are made up of bone cells 
enveloping a central canal called the Haversian canal. Neighboring osteons are 
connected by Volkmann's canals at right angles, allowing direct 
communications between the bone cells across the structure. Osteons are 
metabolically active site where bone resorption and bone formation take place. 
Beneath the cortical layer is the trabecular layer that is made up of 
crisscrossing trabeculae forming a mesh-like structure with open spaces in-
between. Within these irregular open spaces are bone marrow and 
hematopoietic stem cells. These stem cells will later develop into platelets, red 
blood cells and white blood cells. The bone is a metabolically active tissue and 
contains several different cell types that are involved in the maintenance, 
break down, construction and mineralization of bone tissue.  The unique 
trabecular structure, with its honeycomb-like configuration, contributes to the 
bone’s light-weight but yet strong structure so as to support the bone’s 
mechanical functions. 
1.2. Bone Cells 
The main cell types that are found in the bones are: osteoblasts, 
osteoclasts, and osteocytes. The cells are bathed in an extracellular matrix that 
consists of both organic and inorganic components. The organic portion is 
composed mainly of collagen that is a structural protein that gives the matrix 
its gelatinous consistency and contributes to the bone’s tensile strength. The 
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inorganic portion is composed primarily of hydroxyapatite, which is the salt of 
calcium and phosphate, and contributes to the bone’s compressional strength. 
Other minerals such as magnesium, sodium, potassium and carbonate are also 
often found in trace quantities in the bone matrix. Osteoblasts are responsible 
for building new bones while osteoclasts break down bone. Osteocytes have 
the function of regulating the balance of bone resorption and formation. 
 Osteoblasts are single nuclei cells that are involved in the synthesis of 
new bone materials. Osteoblasts originate from the multipotent mesenchymal 
stem cells (MSCs), under the influence of transcription factors such as Runx2 
(Runt-related transcription factor 2), Dlx5 (distal-less homeobox 5) and Msx2 
(Msh homeobox 2)
5
. These local factors induce the MSCs to commit and 
develop into preosteoblasts. The differentiation of preosteoblast into osteoblast 
takes several different stages, identified by different cell surface chemical 
markers, with Wnt signaling playing critical role to push the cells through 
these different developmental phases. Besides Wnt signal, other factors, such 
as estrogens, glucocorticoid, vitamin D, parathyroid hormone (PTH) and 
transforming growth factor beta (TGF-β), also play important function in the 
osteoblastic maturation. PTH is thought to induce osteoblast maturation by 
engaging the PTH receptors that are found on the preosteoblast surface
6–9
. In 
the process of bone formation, osteoblasts function as a group with 
neighboring cells. The consortium of osteoblast secretes specific protein which 
forms an unmineralized matrix layer, called an osteoid, on existing bone 
surfaces. The osteoid are then mineralized by incorporating extracellular 






Osteoclasts, on the other hand, are large multinucleated cell that are 
involved in the resorption of bone tissue. Osteoclasts originate from 
hematopoietic stem cells (HSCs). Under the M-CSF (Macrophage colony-
stimulating factor) influence, HSCs differentiate into preosteoclasts that 
circulate in the blood stream. The preosteoclasts are recruited to bone 
resorption sites where they will fuse to form mature osteoclasts under M-CSF 
and RANKL (receptor activator of nuclear factor κB ligand) signaling. The 
mature osteoclast adheres to the bone surface to be resorbed and secretes a 
myriad of factors that lower the pH of the contact surface, demineralize the 
bone and aid in the removal of the organic structure. The calcium will then be 
released into the surrounding matrix and recycled back into the circulation.  
 Osteocytes are the most abundant cells in the mature bone. During 
bone formation, some of the osteoblasts become encased in the mineralized 
bone and these cells subsequently become osteocytes. Osteocytes have long 
processes that stretch out from the cell body and these processes links one 
osteocyte to another osteocyte in an elaborate network, much like the neuronal 
network. Each osteocyte occupies a lacuna that is bathed in extracellular fluid. 
Through various mechanosensory mechanisms, osteocytes detect stresses or 
fracture in the bone tissue and send out signals to initiate bone remodeling. 
Surprisingly, the osteocytes also secrete fibroblast growth factor 23 (FGF23) 
for renal control of serum phosphate levels
11,12
, suggesting that bone plays a 
role in the renal mineral homeostasis. 
Bone remodeling is a process by which bone tissue is broken down 
coupled by subsequent new bone replacement. Bone remodeling requires the 
tight regulation of osteoclastic and osteoblastic actions. Osteoclast formation 
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requires the presence of RANKL and M-CSF. These membrane-bound 
proteins are produced by neighbouring stromal cells and osteoblasts, and 
require the osteoclast precursors to have direct contact with these nearby cells 
to initiate the maturation cascade of osteoclast development. It was recognized 
that the RANK-RANKL-OPG pathways is an important regulatory mechanism 
that controls the osteoclastic action. The preosteoclasts express membrane-
bound receptor activator of nuclear factor κB (RANK)13, while the 
preosteoblasts express RANKL on the cell surface. RANKL binds to RANK 
on the preosteoclast, triggering the maturation into active osteoclast and 
activating the resorption process
4,6,13–15
. Osteoclastic activation, however, can 
be negatively countered by osteoprotegerin (OPG). OPG is a soluble receptor 
secreted by osteoblasts and binds to the RANKL thereby competitively 
antagonizing the RANK-RANKL binding, leading to less osteoclast 
activation. This mechanism of osteoblast and osteoclast control is basis for the 
anti-OPG antibody therapy as an anti-resorptive treatment for osteoporosis. In 
contrast, bone modeling decouples the bone resorption and formation, where 
these two processes do not have to occur on the same bone surfaces
16
. Bone 
modeling is an important activity during the growth period where bones 
acquire mass and shape their morphology. This process of bone modeling 
occurs throughout the human lifetime and is needed to adapt the bone to 
changing mechanical loading.  
1.3. Osteoporosis 
 Osteoporosis is the thinning of bone tissue and loss of bone density 
over time, which results in the increased risk of fracture
17
. According to the 
World Health Organization (WHO) classification, osteoporosis is defined as a 
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patient who has a bone mineral density (BMD) at the hip or spine that is 2.5 
standard deviations or more below that of normal healthy controls
18
. It is 
estimated that 200 million people worldwide have osteoporosis
19
. While 
osteoporosis is often described as a “silent disease” because there are often no 
symptoms or cause slight pain in the bone and muscle in more severe cases; it 
can potentially cause debilitating complications and has high burden of 
disease
20
. The most severe consequence of osteoporosis is fracture. 
Worldwide, there may be as many as 9 million osteoporotic fractures, of 
which 1.6 million are in the hip
21
. These fractures place a huge economic 
burden on the society
20
. It is estimated that more than 2 million osteoporotic 
fractures occur in the United States (US) each year, at a cost of more than $17 
billion
22
. At the individual level, fractures occur commonly at the spine, hip, 
arms and the humerus and these causes immense pain, disability and death. 
Fracture at the hip often requires extended hospital care and more severe 
fractures often limit a person’s mobility and require assistance in daily 
activities. Although osteoporotic fractures do not directly cause death, high 
morbidity often follows fracture incidences
23
.  
Osteoporosis can be prevented and treated. Even after the development 
of a fracture, the risk of subsequent fractures can be reduced with therapy. 
Osteoporosis occurs in both women and men, but is most common in women 
after menopause, when decreases in estrogen levels lead to an imbalance 
between dynamic mechanisms regulating bone resorption (osteoclast cells) 
and bone formation (osteoblast cells)
24
.  Current available treatments of 
osteoporosis can be broadly classified into two groups: anti-resorptive agents 
and anabolic agents. Additionally, osteoporotic patients can benefit from 
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agents that seek to improve the calcium balance. For early osteoporotic 
patients, restoring calcium homeostasis and bone metabolism can be a 
treatment option. There are many different therapies available to achieve this 
purpose and they include calcium and vitamin D supplements, calcitonin-
salmon and strontium.  
There are many different anti-resorptive agents in the market and they 
work by preventing the breakdown of bone through various mechanisms. 
Examples of anti-resorptive agents include selective estrogen receptor 
modulators (SERMs, e.g., raloxifene), bisphosphonates (e.g., alendronate) and, 
denosumab, which is a fully humanized antibody neutralizing RANKL
25
. 
These different drug classes target the different pathways of osteoclast 
activation and reduce the resorption of the bone. SERMs regulate the estrogen 
levels and decrease the pro-inflammatory factors that enhance osteoclast 
activity
26
. Bisphosphonates has been in clinical use for the treatment of 
calcium-related bone disease for the past 40 years
27,28
. They have inhibitory 
properties on the osteoclast survival and activity
29
. There are many different 
bisphosphonates available for the treatment or prevention of osteoporosis. 
Most of the modern bisphosphates are nitrogenous bisphosphonates. The 
nitrogenous bisphosphonates work by interfering with the melavonate pathway 
for cholesterol production and disrupting the proper formation of protein post-
translational modification. This leads to disruption in small GTPases 
production and eventually affecting the resorptive activities of osteoclasts.  
Some examples of nitrogenous bisphosphonates include alendronate, 
ibandronate, and zoledronate. The different bisphosphonates differ in potency, 
dosage form and dosing frequency. Because of its bone specificity, positive 
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effect on BMD and fracture rate reduction, bisphosphonate is being used 
clinically for the treatment for osteoporosis and many other bone-related 
diseases
30
. Denosumab is a fully humanized antibody neutralizing RANKL 
approved by the FDA in 2010. Denosumab works by sequestering RANKL 
and removes the activating signal for maturation of pre-osteoclasts and thereby 
reduce the resorption of the bone. Denosumab provides another antiresorptive 
treatment option to patients who cannot tolerate bisphosphonates
31
. 
The options for anabolic drug treatment, on the other hand, are limited. 
The only options available currently are parathyroid hormone (PTH) 1-34 
(teriparatide, Forteo®) and PTH 1-84 (Preotact®). Teriparatide, at a 
subcutaneous (SC) dose of 20 μg daily, is available in the US and Europe for 
the treatment of osteoporosis in both men and women at high risk for 
osteoporotic fracture, while PTH 1-84 is currently approved only in Europe. 
PTH is secreted by the parathyroid glands to increase the concentration of 
calcium in the blood by releasing the calcium store in the bone, thereby 
playing an important role in calcium homeostasis. PTH stimulates the bone 
resorption process and increases calcium release from the bone. In fact, if PTH 
is given continuously, bone resorption is increased leading to bone loss and 
weaker bone. Interestingly, PTH when given intermittently has the opposite 
effect of stimulating bone growth. This can be understood as the coupling of 
bone resorption and formation in bone remodeling. Osteoblasts are stimulated 
by the resorption signals and the intermittent PTH exposure generates more 
osteoblastic than osteoclastic response, resulting in more bone formation 
activities. Both teriparatide and PTH 1-84 are administered daily via SC 
injection. In a toxicology study done in rats, high dosage and prolonged use of 
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teriparatide was associated with tumor growth in the bones
32
. However, FDA 
considers the risk of osteosarcoma in humans is remote and “extremely rare” 
and no osteosarcoma was reported in the large registration trial involving 
approximately 2800 patients
32–34
. PTH therapy is therefore limited to 2 years. 
As peptide products, both teriparatide and PTH 1-84 require daily dosing by 
SC injection. There exists a need for an agent with enhanced bone building 
efficacy, no restriction on duration of treatment, and less frequent dosing 
relative to PTH. 
1.4. Targeting the Wnt Pathway 
Wnt signaling pathway is gaining recognition for its role in both bone 
modeling and bone remodeling processes
4,16,35
. Wnt signaling activation 
initiates both bone remodeling and bone modeling which increase bone 
formation in excess of bone resorption resulting in increased bone mass
16
. 
Also, the loss-of-function of downstream Wnt signal molecules causes weak 
bone diseases, suggesting that Wnt has an important role in stimulating bone 
formation. Wnts are cysteine-rich, secreted glycoproteins that bind to the cell 
surface receptor Frizzled (Fzd) and co-receptor low-density lipoprotein 
receptor-related proteins 5 or 6 (Lrp5/6).  The binding of Wnt ligand to the 
receptor and co-receptors can stimulate a variety of downstream signals and 
the major one being the β-catenin pathway. In the canonical β-catenin 
pathway, binding of the Wnt ligand to the Frizzled receptor activates it and 
initiates the recruitment and activation of a cytoplasmic phosphoprotein 
Disheveled (Dsh). Dsh then inhibits the cytoplasmic complex, composed of 
glycogen synthase kinase 3 beta (Gsk-3β), Axin, and adenomatous polyposis 
coli (APC) which binds to β-catenin, and prevents the degradation of β-
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catenin. This raises the β-catenin levels in the cytoplasm and facilitates its 
translocation into the cell nucleus and where it functions as transcription factor 
to increase the gene expression of principal bone formation proteins. 
Hoeppner, Secreto, & Westendorf (2009)
36
 reviewed a list of molecules 
involved in the Wnt signaling pathway and how altering these individual 
components impact the bone phenotype. These are potential drug targets for 
the treatment of osteoporosis and they can generally be classified into two 
classes: intracellular and extracellular. 
Within the cell, Gsk-3β is a critical molecule that phosphorylates the β-
catenin and targets it for degradation when Wnt signal is absent. Therefore, a 
treatment strategy for increasing the bone formation is to inhibit Gsk-3β. And 
indeed several specific Gsk-3β inhibitors or general inhibitors (e.g., lithium 
metal ions) were demonstrated to increase BMD
37–39
. One possible difficulty 
with such a treatment is that Gsk-3β is a kinase that is involved in many other 
signaling pathways and implicated in many other diseases such as diabetes and 
Alzheimer's disease
40,41
. Targeting this protein for the treatment of bone 
disease might have adverse effects on other physiological functions.  
Outside the cells, sclerostin and Dickkopf-1 (DKK-1) are natural 





 that negatively regulates the bone formation 
process. Sclerostin binds to LRP5/6 receptors, blocking Wnt from binding to 
its receptors and thereby inhibiting the Wnt signaling pathway
44
.  Loss-of-
function of the SOST gene that encodes for sclerostin leads to painful bone 
overgrowth diseases such as sclerosteosis and van Buchem disease
42
.  
Additionally, intermittent PTH, a proven bone formation treatment, is 
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associated with sclerostin inhibition
45,46
.  Sclerostin, therefore, makes a good 
drug target for the treatment of osteoporosis due to its specificity to the bone 
and cartilage cells. The association between low level of sclerostin and high 




 The use of anti-sclerostin antibody in animals demonstrates the 
viability of this agent as a bone formation therapy.  Sclerostin inhibition 
reversed bone loss in estrogen-deficient rats and rats with chronic 
inflammation as well as increased the bone mass and bone strength for normal 
rats and enhanced fracture healing
49–53
.  Similarly, sclerostin inhibition in 
cynomolgus monkeys increased bone formation and improved bone mass and 
strength
54
.  Human trials of anti-sclerostin antibody also demonstrated that the 
treatment increased bone formation markers and improved the BMD
55–60
. 
1.5. Development of Anti-Sclerostin Therapy for 
Osteoporosis Treatment 
BPS804 is an anti-sclerostin antibody being developed by Novartis. 
Four completed clinical trials were posted in the ClinicalTrials.gov website. 
These included clinical pharmacology trials to characterize pharmacokinetics 





, and in patients with renal function deficiencies
63
. 
BPS804 was also investigated for safety and efficacy in PMP women with low 
BMD following multiple dosing in a randomized, investigator and subject 
blind, placebo-controlled phase 2 trial
64
. No results were posted so far.  
Romosozumab (also known as AMG785) is an anti-sclerostin antibody 
being co-developed by Amgen and UCB for osteoporosis in PMP women. 
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Phase 3 trials are currently on-going
65–68
  and completed phase 2 trials include 
trials investigating multiple dose range
69
, effects on fracture healing
69,70
 and 
efficacy, safety and tolerability in PMP women. Completed phase 1 trials 
include single and multiple dose escalation studies
71,72





, previous bisphosphonate exposure
75




In the phase 1 single dose and multiple dose studies, PK analysis 
shows that romosozumab demonstrated nonlinear kinetics that is typical of 
monoclonal antibodies (mAbs)
77
. The half-life of romosozumab was estimated 
to be about one week and serum exposure increased more than dose 
proportional
55,56
. Following romosozumab administration, there were dose-
dependent increases in bone formation markers. In the phase 1 multiple dose 
study, the bone formation markers procollagen type I N-terminal propeptide 
(P1NP), bone-specific alkaline phosphatase (BSAP) and osteocalcin peaked at 
148%, 67% and 90% from baseline respectively after 3mg/kg SC once every 
four weeks (Q4W). Lumbar spine and total hip BMD increased 7% and 4% 
from baseline at 18 weeks following three doses of 3mg/kg Q4W SC
56
.  
The phase 2 romosozumab trial investigated SC romosozumab 
administered monthly (QM) and quarterly (Q3M). The dosing arms included 
70mg QM, 140mg QM, 210mg QM, 140mg Q3M and 210mg Q3M 
administered for 2 year followed by one year of denosumab or placebo
58,60
. 
Following a two-year treatment of 210mg QM romosozumab regimen, lumbar 
spine BMD increase 11.3% and 15.7% from baseline at 12 and 24 months 
respectively
58
; and subsequently the subjects were randomized to either 60mg 
denosumab once half-yearly (Q6M) or placebo for one year, with 
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denomsumab treatment maintaining and increasing the lumbar spine BMD to 
19.1% at 36 months, while placebo treatment resulted in lumbar spine BMD 
returning towards baseline level at 4.6% at 36 months
60
. 
1.6. Development of Blosozumab 
Blosozumab is a humanized immunoglobulin G4 (IgG4) anti-sclerostin 
mAb, for the treatment of osteoporosis in PMP women. There were six clinical 
studies (5 phase 1 studies and one phase 2 study) conducted to date
57,78–82
.  
Two phase 1, single dose and multiple ascending dose clinical studies 
was reported and demonstrated the safety, tolerability and characterize the PK 
and PD properties of blosozumab
57
. Single and multiple doses of intravenous 
(IV) and SC blosozumab were given to PMP women for up to single 750mg 
IV and 750mg Q2W for 8 weeks. The top dose regimen for SC administration 
was 270mg Q2W for 8 weeks. Bone formation biomarkers showed an increase 
in P1NP, BSAP and osteoclacin following five SC doses of 270mg Q2W were 
212%, 107% and 94% respectively. The lumbar spine BMD increased 5.61% 
at 3 months after 270mg Q2W treatment for 8 weeks
57
. Following a one-year 
administration of SC 270mg Q2W blosozumab, lumbar spine BMD increased 
18% from pre-treatment level and bone formation biomarkers also showed 
positive increase
59
. The increase in bone mass resulting from anti-sclerostin 
therapy is larger than PTH treatment
83
. 
Despite the deep knowledge in bone biology, osteoporosis etiology and 
mechanism of drug action, to aid in target selection; the development of new 
drug product for osteoporosis remains an expensive and time-consuming 
endeavor. It was estimated that to successfully bring a drug into market, it 
costs between US$500 million to US$2 billion depending on the disease, type 
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of drugs and development strategy
84
; with the clinical phase of drug 
development process being the most costly and laborious. To gain approval 
from the regulatory agencies for a new osteoporosis therapy, demonstration of 
the potential drug’s ability to reduce fracture rates is required. This proves to 
be a major hurdle where large studies are required to demonstrate statistically 
significant reduction in fracture incidences. Early proof-of-concept trials use 
BMD as a surrogate to predict bone strength and fracture risk reduction. 
Granted that BMD is a good indicator for bone strength and fracture risk
85
, the 
observation period requires three months to one year for meaningful bone 
accruement. Besides, BMD is not the only factor that determines the bone 
strength, bone turnover markers are also useful indicators that can potentially 
inform efficacy of new drug products in improving bone strength
85
. 
Additionally, adequate dosing regimen is crucial to improve efficacy and 
reduce adverse effects. Many drugs failed clinical development because of 
inefficacious dose or due to adverse effects occurrence.  
With so many variables playing a part in the drug development of new 
osteoporotic treatments, a systematic approach to integrate all useful 
information using mathematical and computational power is becoming more 
critical.  Model-based drug development can play a part to aid the drug 
development process by integrating the myriad of information through 
mathematical formulation, then using the model to test hypothesis, such as 
different dose regimens, in virtual patient populations. This increases the 
scientific awareness of the disease and drug characteristics as well as reduces 
the patient burden in clinical trials by selecting the optimal sample size and 
dose regimen. Increasingly, regulators are accepting modeling and simulation 
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in supporting drug development
86
. More recently, regulators are accepting 
drug product labels to be based on model-based scientific reasoning instead of 






2. Objectives  
 In this project, we aimed to demonstrate the utility of model and 
simulation in supporting the drug development of anti-sclerostin therapy for 
the treatment of osteoporosis. We constructed PK-PD models to describe the 
drug exposure-response relationship using the nonlinear mixed effects 
approach. We also developed a systems pharmacology model that describes 
the underlying biology of sclerostin regulation on bone cell homeostasis. The 
models were then used to predict the optimal dose regimens for the anti-
sclerostin mAb for the treatment of osteoporosis. 
This project is organized into three parts. The first part described the 
population PK-PD modeling and simulation approach for analyzing the 
clinical data collected from the blosozumab trials and discussed the 
methodology for analyzing a patient level meta-analysis dataset comprised of 
three phase 1 and one phase 2 blosozumab clinical trials  (Sections 3 and 4). 
The second part described the systems modeling approach to integrate current 
knowledge of the bone biology with the sclerostin’s mechanism of regulating 
bone remodeling (Sections 5 and 6). In the third part, we then compared the 
population PK-PD model and the systems biology model and discuss the 
appropriateness for using either model for predicting efficacy responses for 
different dose regimens of anti-sclerostin therapy. Simulation experiments 
were also performed using both population PK-PD and the systems biology 
model to investigate the how dose, dosing frequencies and covariate effects 
impacted drug exposures and clinical efficacy responses (Section 7). 
In the first part, we aimed to build a population PK-PD model to 
characterize exposure-response relationship between serum blosozumab 
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concentration and lumbar spine and hip BMD and their disease progression. 
The model will help identify important patient factors (covariates) that have 
impact on the absorption, disposition and elimination of blosozumab as well as 
efficacy responses and BMD deterioration in PMP women. The population 
modeling approach allows information from different clinical trials to be 
assimilated and variability to be quantified. The PK-PD model incorporated 
the understanding of the mechanism of action of the drug and its impact on the 
outcome response into a mathematical framework that allowed us to perform 
simulations for investigating efficacious and safe dose regimens, within drug 
exposures tested in clinical trials, for subsequent studies.  
In the second part, a systems biology modeling and simulation 
approach was utilized to model the interactions involved in osteoblast and 
osteoclast homeostasis. We started with a published bone remodeling model 
that had been widely used to model different osteoporosis therapies and 
incorporated current knowledge of the impact of sclerostin on the bone 
remodeling process
6,90
.  The bone remodeling model described the interaction 
between osteoblast and osteoclast through the RANK-RANKL-OPG axis and 
TGF-β feedback. The sclerostin effect on osteoblast and osteoclast regulation 
was proposed and added to the bone remodeling model. A BMD model then 
linked the bone homeostasis model to the phase 2 primary clinical endpoint. 
The extended model was able to characterize the bone formation and 
resorption markers and linked the osteoblast and osteoclast actions to changes 
in BMD, allowing for simulation experiments to investigate the optimal 
dosing regimen beyond the dose regimens tested in the clinical trials.  
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Lastly, we compared the performance of the population PK-PD model 
and the systems biology model and discuss the strengths and limitations and 




3. Population PK-PD Models of Blosozumab Materials 
and Methods 
3.1. Blosozumab Clinical Studies Background 
Blosozumab is a humanized IgG4 mAb targeted against sclerostin, 
which is a naturally occurring protein produced by osteocytes and is a negative 
regulator of bone formation.  Blocking the action of sclerostin leads to 
promotion of bone formation that is not associated with increased resorption. 
Three phase 1 and one phase 2 clinical studies have been completed and are 
included in this meta-analysis to characterize the PK profile and explore 
exposure-PD response relationship.  
Figure 1 shows the schematic representation of the study design for the 
four blosozumab clinical studies. Study 1 was a first-in-human, single dose-
escalation Phase 1 study to assess blosozumab.  Rich PK profile, PD response, 
and immunogenicity (development of anti-drug antibody) following single IV 
and SC doses of blosozumab were collected. The study was a randomized, 
parallel-design, investigator and subject blind, placebo-controlled, single-dose, 
dose-escalation study in PMP women, exploring the doses 7.5, 25, 75, 225, 
and 750mg as IV infusion and 150 mg administered by SC injection. Study 1 
included an open-label phase where subjects who have previously been 
exposed to bisphosphonates were randomized to receive either 225 mg IV or 
750 mg IV of blosozumab. Following study drug administration, all subjects 
were followed for 12 weeks for safety, PK, and PD assessments. 
Study 2 was a Phase 1 study to investigate the safety and tolerability as 
well as to evaluate the PK profile and bone biomarker responses following 
single IV and SC doses of blosozumab in Japanese subjects.  Study 2 was a 
placebo-controlled, investigator and subject blind, randomized, single-dose 
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study in Japanese men and Japanese PMP women, exploring the doses 75, 750 
and 1100 mg administered as IV infusion and 150 mg as SC injection. Dense 
PK and PD samples were collected to characterize the PK and biomarker 
responses in Japanese subjects. 
Study 3 was a multiple ascending dose Phase 1 study to evaluate 
blosozumab in healthy PMP women. Study 3 was a multicenter, randomized, 
investigator and subject blind, placebo-controlled, parallel-design study, 
investigating the doses 180 mg SC Q4W, 270 mg SC Q4W, 270 mg SC Q2W, 
540 mg IV Q4W, and 750 mg IV Q2W. Blosozumab or placebo was dosed 
every other week for all dosing arms, with the final dose administered at Week 
8. Subjects were followed up for an additional 12 weeks after the final dose of 
study drug. Trough PK samples during intermediate doses, and dense PK 
samples after the last dose, were collected to characterize blosozumab PK at 
steady state. Biomarkers samples were also collected to investigate the 
mechanism of action of anti-sclerostin treatment on bone formation and 
resorption. 
 Study 4 was a one-year phase 2 study with an additional one-year 
follow-up in PMP women with low BMD, defined as a T-score between -3.5 
and -2.0, inclusive. Study 4 was a phase 2, randomized, parallel design, 
investigator and subject blind, placebo-controlled study, investigating the 
doses 180 mg every Q4W, 180 mg Q2W, 270 mg Q2W, 270 mg Q12W (once 
every 12 weeks) administered by SC injections.  All patients also received a 4- 
to 8-weeks run-in period of treatment with calcium (1000 mg/kg/day) and 
Vitamin D (1000 IU/day). Sparse PK sampling strategy was utilized due to the 
outpatient nature of the study design.  
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Of note, there was a change in the manufacturing process during the 
clinical development and two blosozumab formulations were used in the 
clinical investigations; studies 1 and 2 used formulation 1 while studies 3 and 







Abbreviations: BP=prior bisphosphonate exposure; 
IV=intravenous infusion;  
Q2W= once every 2 weeks; Q4W= once every 4 weeks; 
Q12W= once every 12 weeks; SC=subcutaneous.  
 
  = 7-day safety evaluation after first dose in each cohort  
  = remaining subjects in each cohort receives blosozumab or 
placebo, one subject per day 
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3.1.1. Sample Collections 
Studies 1 to 3 collected rich PK samples that covered the absorption, 
distribution and elimination phases of blosozumab concentration-time profile 
and allowed for good characterization of the PK properties. Study 4 collected 
sparse PK samples that were mainly trough pre-dose samples. The samples 
were analyzed for blosozumab using a validated enzyme-linked 
immunosorbent assay (ELISA) method.  The lower limit of quantification was 
200 ng/mL, and the upper limit of quantification was 12,800 ng/mL.  Samples above 
the limit of quantification were diluted and reanalyzed to yield results within the 
calibrated range.  The inter-assay accuracy (% relative error) during validation ranged 
from 0.266% to 13.7%.  The inter-assay precision (% relative standard deviation) 
during validation ranged from 1.02% to 8.10%.  Blosozumab was stable for up to 603 
days when stored at approximately -70 °C. The samples were analyzed at ICON 
Development Solutions, LLC located in Whitesboro, New York, USA.   
BMDs at various skeletal sites were collected, including the lumbar 
spine and the hip, and assessed by dual energy x-ray absorptiometry (DXA) 
using either Hologic or Lunar equipment in study 4. Initial densitometry 
results were interpreted at the individual study centers so that study 
investigators can exclude patients who obviously fail to meet the BMD entry 
criterion. The baseline and all subsequent bone density scans were submitted 
directly to the central quality assurance center. Systematic differences in BMD 
obtained with the Hologic and Lunar equipment were reconciled by employing 
a cross-calibration adjustment method developed and routinely used by the 
central quality assurance center.  
 24 
 
For the purpose of PK-PD modeling, the Lunar BMD readings were 
standardized to Hologic equivalent. The formula for recalculating the Lunar 
BMD readings into Hologic equivalent readings are shown in (E.1 and E.2) 





𝐻𝑜𝑙𝑜𝑔𝑖𝑐 𝑇𝑜𝑡𝑎𝑙 𝐻𝑖𝑝 𝐵𝑀𝐷 𝑒𝑞𝑢𝑖𝑣𝑎𝑙𝑒𝑛𝑡 =  







3.1.2. PK-PD Dataset Preparation 
Blosozumab serum concentrations were combined with dosing 
information, covariate data (for example, gender, body weight, habits, clinical 
lab data) using S-Plus (version 8.2, TIBCO Software Inc., Somerville, 
Massachusetts, USA) to produce the NONMEM meta-analysis dataset for 
population PK/PD analysis.   
3.1.2.1. Independent variable  
Missing patient characteristic data were imputed based on the 
following criteria. When all independent variable values for a patient are 
missing, then the median value of patient population was used as an imputed 
value.  When some independent variables for a patient are missing, data were 
imputed, within a patient, using the last observation carried forward (LOCF) 
method and missing baseline values of independent variables were imputed 
backward. 
3.1.2.2. PK data 
The final PK analysis dataset pooled together three phase 1 studies and 
one phase 2 study. Extreme data points in the dataset were evaluated using an 
outlier range test to determine if they should be included in the analysis. The 
range test was performed by computing the arithmetic mean and standard 
deviation of the log-transformed values of all blosozumab concentrations, 
except for the most extreme value, and stratified by dose and elapsed time. If 
the most extreme value was outside the range of three standard deviations 
below and above the arithmetic mean of the log-transformed values, then the 
extreme data point was deemed an outlier and excluded from the analysis. 
Suspected outlying data were examined one at a time. Other suspicious 
outlying data points were inspected individually and reasons for exclusion in 
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the analysis were documented. After excluding outlying records and samples 
that were below quantitation limits (BQL), the final PK analysis dataset 
contained 1744 observations from 225 subjects who received blosozumab 
treatment. Of which 450 observation from 48 subjects were from study 1, 187 
observations from 18 subjects were from study 2, 543 observations from 44 
subjects were from study 3 and 564 observations from 116 subjects were from 
study 4. 
3.1.2.3. BMD data 
The BMD data for the analyses were from Study 4 only.  Compared 
with Phase 1 studies, the design of the Phase 2 study better represents a Phase 
3 study in terms of longer treatment duration, more comparable subjects, and 
more extended BMD measurements.  Specifically, the BMD measures in all 
Phase 1 studies were conducted up to 3 months following the first blosozumab 
dose. This led to high variability due to relatively small magnitude of changes 
and was not ideal to provide inferences on the trajectory of the BMD 
responses following chronic repeated treatment.  Immunogenicity that 
occurred in one subject in phase 2 impacted blosozumab exposure and BMD 
responses and this subject was excluded from the analysis. In summary, the 
BMD analysis dataset consisted of 997 lumbar spine and 854 total hip BMD 
observations from 152 subjects who received placebo or blosozumab 




3.2. Population Pharmacokinetic/Pharmacodynamics 
Modeling Strategy 
3.2.1. General PK/PD Model Development Approach 
A population analysis approach was used to characterize the time 
course of blosozumab serum concentrations following administration of 
blosozumab as well as the BMD profiles following placebo and blosozumab 
treatments.  Nonlinear mixed-effect population analysis was conducted with 
NONMEM (Version VII, ICON Development Solutions, Ellicott City, 
Maryland, USA) with or without Perl-Speaks NONMEM (PsN, version 3.6.2) 
as an interface to run NONMEM.  R (version 3.1.0) and Xpose 4 or S-Plus 
(version 8.2, TIBCO Software Inc., Somerville, Massachusetts, USA) were 
used for diagnostic plots. 
The general process for the model development was as follows and an 
overview is depicted in Figure 2. A base structural model was first identified 
to describe the kinetics profile of blosozumab and BMD. The PK and PD 
kinetic models were coded in differential equations and ADVAN6 TRANS1 
subroutine together with the First-Order Conditional Estimation with 
Interaction (FOCE-I) method was utilized to fit the model to the observed 
data. 
Models for inter-individual variability were examined on parameter 
estimates as shown in (E.3) whereby P represents individual empirical Bayes 
estimate (EBE), θμ represents the mean parameter value, and η is a random 
variable with a mean of 0 and variance of ω2. 
 𝑃 =  𝜃𝜇 ∙ 𝑒




 Combined proportional and additional residual error model was 
selected which best described the difference between model-predictions and 
the observed concentration (E.4) 
 𝑌𝑖𝑗  =  𝐼𝑃𝑅𝐸𝐷 ∙ (1 + 𝜀1) + 𝜀2 ,   where 𝜀 ~𝑁(0, 𝜎
2) E.4 
where Yij is the j
th
 observation in the i
th
 subject, IPRED is the model predicted 
blosozumab concentration in that individual, residual random error (ε) is a 
random variable normally distributed with a mean of zero and variance σ2, and 
the estimated σ2 accounts for variability in the bioanalytical assay, and errors 
associated with dose administration and sample collection, as well as errors 
with data transcription of dosing and sample collection time. . 
The base model was examined for the precision of the parameter 
estimates using standard error estimates as well as 95% confidence interval 
obtained using log-likelihood profiling. 
Once an appropriate base model had been identified, the potential 
covariates were investigated for their effects on the individual parameters 
estimates. Potential covariates were evaluated based on the improvement of 
model fit using the log-likelihood test as well as on the magnitude of reduction 
in the inter-individual variability on the parameter estimates tested. The 
relationship between each factor and a PK parameter was assessed using a 
variety of linear and nonlinear models for continuous covariates (E.5 to E.7) 
and categorical covariates (E.8). 
 𝑃 =  𝜃𝜇 + 𝜃𝑐𝑜𝑣 ∙ (𝐶𝑂𝑉 −𝑚𝑒𝑑𝑖𝑎𝑛) E.5 
 𝑃 =  𝜃𝜇 ∙ 𝑒
𝜃𝑐𝑜𝑣∙(𝐶𝑂𝑉−𝑚𝑒𝑑𝑖𝑎𝑛) E.6 
 








 𝑃 =  𝜃𝜇 ∙ (1 + 𝐼𝑁𝐷 ∙ 𝜃𝑐𝑜𝑣) E.8 
 
where P is the individual’s estimate of the parameter, θµ represents the typical 
population value of the parameter, θcov represents the effect of the covariate, 
COV is the value of the covariate, MED median represents the median value 
of all values for the covariate, and IND is a dichotomous indicator variable 
with values of 1 or 0 that represents presence or absence of the covariate 
effect..  
Covariates were introduced into the model using a stepwise forward 
addition and backward elimination method
91
. If the addition of the covariate to 
the model improved the model fit with at least 6.635 points reduction (χ2 
distribution, 1 degree of freedom, p <0.01) in the objective function value 
(OFV) and a reduction in the inter-individual variability, the covariate will be 
retained and added to the full model. Highly correlated or physiologically-
related factors (such as weight and body mass index [BMI]) will be evaluated 
individually in the base model, and the most relevant covariate retained. For 
example, if both body weight and BMI resulted in similar improvement in 
model fit (similar reduction in objective function value and interindividual 
variability), body weight will be retained in the final model as it is a more 
useful patient factor that is routinely taken clinically.  
Once the full model had been established, the significance of the 
potential covariates was evaluated using a backward selection (model 
reduction) technique.  Beginning with the full model, each covariate was 
individually removed and its effect on the OFV evaluated.  The least 
significant covariate not resulting in an increase 10.828 points (χ2 
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distribution, 1 degree of freedom, p <0.001) was dropped.  The reduced model 
was successively refitted by applying the same reduction technique and 
criterion until all remaining covariates were deemed statistically significant.  
3.2.2. Model Evaluation 
3.2.2.1. Goodness-of-fit and Residuals Diagnostic Plots 
Model predictions and observations were plotted to visually examine 
the fit. Residuals errors were plotted against the model predictions and 
visually inspected for trends of deviations. 
3.2.2.2. Visual Predictive Check 
Visual predictive check (VPC) was performed on the model to ensure 
that the model maintained fidelity with the data used to develop it.  The 
simulation dataset was based on replicating the patients in the final dataset 
1000 times and comparing simulated data against observed PK data, taking 
into account variability in all parameters, as given by the inter-individual 
variability and residual error terms.  The distributions of simulated 
concentrations, conditional on the posterior distribution of model parameters, 
were compared to the actual concentration distributions as stratified by dose to 
ensure concordance.  
3.2.2.3. Bootstrap Analysis 
1000 bootstrap analyses sampling the analysis dataset with replacement, and 
stratified by study  to maintain the proportion  of dense and sparse PK 






Abbreviation: d.f.=degree of freedom; %SEE = standard error of estimate. 
Figure 2 General process for pharmacokinetic and 








Evaluate parameter estimate precision, eg. %SEE 
and sensitivity analysis
• Evaluate parameter estimate precision
• Log-likelihood ratio test 
objective function values decrease > 6.635 (χ2, 1.d.f. p=0.01) 
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3.2.3. Pharmacokinetic Model 
3.2.3.1. Base Model Development 
A two-compartment open model, where blosozumab was assumed to 
be eliminated from the central compartment, was identified as optimal to 
describe the PK profile.  A schematic representation of this model is shown in 
Figure 3. The differential equations describing the mass balance of the drug 
following IV infusion or SC injection are as (E.9 to E.11). PK parameters 
estimated were clearance (CL), saturable-clearance (CLSAT), Michaelis-
Menten constant (C50), central volume (V), peripheral volume (V2), 
distribution clearance (Q), SC route specific parameters (i.e., first-order 
absorption rate constant from a depot [Ka] and absolute bioavailability [F]).  
All parameters were estimated by fitting the IV and SC data simultaneously. 
Residual error terms (proportional and additive errors) were estimated for each 
study.   
 𝑑(𝐴1)
𝑑𝑡












+ 𝑘) ∙ 𝐴2  E.10 
 𝑑(𝐴3)
𝑑𝑡










 represents the rate of transfer of blosozumab from the central to 
peripheral compartment, 𝑘23 =
𝑄
𝑉2
 represents the rate of transfer of 
blosozumab from the central to peripheral compartment,  𝑘 =
𝐶𝐿
𝑉
 represents the 
rate blosozumab elimination from the central compartment. A1, A2 and A3 
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represent the amount of free drug in the depot, central and peripheral 
compartments respectively. 
 
Abbreviation:  CL = systemic clearance of drug; CL = apparent systemic 
clearance of drug; CLSAT = saturable systemic clearance; F=absolute 
bioavailability; IV= intravenous infusion; Ka = absorption rate constant; Q 
= distribution clearance; SC=subcutaneous. 
 
Figure 3 Schematic representation of the population 
pharmacokinetic model for blosozumab. 
 
3.2.3.2. Covariate Model Development 
Patient factors examined as potential covariates in the PK analysis are 
presented in Table 1. Patient factors were screened graphically for possible 
correlation with NONMEM-derived Bayesian estimates of individual PK 
parameters.  Factors showing visible trend for correlation with a PK parameter 
or anticipated to be physiologically related to a PK parameter were further 




















Table 1 Clinically Relevant Patient Factors Assessed in the 
Population PK Model 
Potential covariate Type of Variable Parameters Tested 
Age Continuous Ka, CL, CLSAT, V, V2 
Body size (body weight, body mass index) Continuous Ka, CL, CLSAT, V, V2 
Baseline sclerostin level Continuous Ka, CL, CLSAT, V, V2 
Ethnic origin Categorical CL, CLSAT, V, V2 
Anti-blosozumab antibodies (neutralizing assay)
a
 Categorical CL, CLSAT 




 The immunogenicity data included in this covariate analysis were restricted to those from 
study 4 because immunogenicity in Phase 1 studies were evaluated by a screening assay 
only, and most immunogenicity positive samples were detected when blosozumab 
concentrations were below the detection limit of the PK assay. 
 
 
3.2.4. Pharmacodynamics Model 
3.2.4.1. Base Model Development 
A schematic representation of the structure model is depicted in Figure 
4. The target-engagement of blosozumab and sclerostin was modeled with two 
differentiation equations representing the kinetics of free target and drug-
target complex (E.12 and E.13). Both the free target and the drug-target 
complex are theoretical quantities and represent the fraction of target in free or 
drug-bound forms, and are comparable to those in a receptor occupancy 
model, i.e., the sum of their quantity is always 1. Before dose administration, 
the values in free target and blosozumab-target complex compartments are 1 
and 0, respectively, indicating the target is 100% in the free form and 0% 
bound to the drug.  After a certain blosozumab dose, if the complete target 
engagement is achieved, the values in the free target compartment and 






=  −𝑘𝑜𝑛 ∙ 𝐶𝑜𝑛𝑐 ∙ 𝐴4 + 𝑘𝑜𝑓𝑓 ∙ 𝐴5 E.12 
   
 𝑑(𝐴5)
𝑑𝑡
=  𝑘𝑜𝑛 ∙ 𝐶𝑜𝑛𝑐 ∙ 𝐴4 − 𝑘𝑜𝑓𝑓 ∙ 𝐴5 E.13 
 
where  𝐾𝐷 =
𝑘𝑜𝑓𝑓
𝑘𝑜𝑛
 represents the binding constant between blosozumab and its 
target, 𝑘𝑜𝑓𝑓  represents dissociation rate constant and 𝑘𝑜𝑛  represents binding 
rate constant. A4 and A5 represent the amount of free unbound target and 
drug-target complex respectively.  
The change in the BMDs, both lumbar spine and total hip, were 
modeled using an indirect response model to reflect delay in the effect and 
drug administration. The blosozumab-target complex was the driving force to 
increase the rate of BMD formation. Observation of the placebo cohort 
showed slight BMD deterioration during the 1-year treatment and 1-year 
observation periods. A zero-order linear disease progression rate was included 




=  𝑘𝑖𝑛𝐿𝑆𝐵𝑀𝐷 ∙ (1 + 𝐸𝑚𝑎𝑥𝐿𝑆𝐵𝑀𝐷 ∙ 𝐴5) + 𝑘𝑜𝑢𝑡𝐿𝑆𝐵𝑀𝐷 ∙ 𝐴6
− 𝑘𝑑𝑖𝑠𝐿𝑆𝐵𝑀𝐷 
E.14 
   
 𝑑(𝐴7)
𝑑𝑡




where 𝑘𝑖𝑛 = 𝑘𝑜𝑢𝑡 ∙ 𝐵𝐿  represents the zero-order rate of BMD formation, 
𝑘𝑜𝑢𝑡  represents the first-order rate of BMD degradation, 𝐵𝐿  represents the 
baseline BMD prior to the start of drug administration, 𝑘𝑜𝑢𝑡 represents the 
first-order rate of BMD destruction, 𝐸𝑚𝑎𝑥 represents maximal the drug effect 
on the rate of BMD formation, and 𝑘𝑑𝑖𝑠  represents the rate of disease 
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progression; 𝐿𝑆𝐵𝑀𝐷 refers to lumbar spine BMD and 𝑇𝐻𝐵𝑀𝐷 refers to total 




Abbreviation:  CL = systemic clearance of drug; CL = apparent systemic 
clearance of drug; CLSAT = saturable systemic clearance; F=absolute 
bioavailability; IV= intravenous infusion; Ka = absorption rate constant; Q 
= distribution clearance; SC=subcutaneous; kon=binding constant; 
koff=dissociation constant; kinLSBMD=rate of lumbar spine BMD formation; 
kinTHBMD=rate of total hip BMD formation; koutLSBMD=rate of lumbar spine 
BMD destruction; koutTHBMD=rate of total hip BMD destruction; 
kdisLSBMD=rate of lumbar spine BMD disease progression; kdisTHBMD=rate 
of total hip BMD disease progression. 
 
Figure 4 Schematic representation of the population target-







































3.2.4.2. Covariate Model Development 
Patient factors examined as potential covariates in the PD analysis are 
presented in Table 2. Patient factors were screened graphically for possible 
correlation with NONMEM-derived Bayesian estimates of individual PK 
parameters.  Factors showing visible trend for correlation with a PD parameter 
or anticipated to be physiologically related to a PD parameter were further 
assessed to confirm and covariate effect on population PD parameters 
Table 2 Clinically Relevant Patient Factors Assessed in the 
Population BMD Models 
Potential covariate Type of Variable Parameters Tested 
Age Continuous BL, kin, KD, EMAX kdis 
Body size (body weight, body mass index) Continuous BL, kin, KD, EMAX kdis 
Baseline sclerostin level Continuous BL, kin, KD, EMAX kdis 
Baseline P1NP level Continuous BL, kin, KD, EMAX kdis 
Baseline BSAP level Continuous BL, kin, KD, EMAX kdis 
Baseline Osteocalcin level Continuous BL, kin, KD, EMAX kdis 
Baseline CTX level Continuous BL, kin, KD, EMAX kdis 
Ethnic origin Categorical BL, kin, KD, EMAX kdis 
Anti-blosozumab antibodies (neutralizing assay) Categorical BL, kin, KD, EMAX kdis 
Anti-blosozumab antibodies (screening assay) Categorical/ 
continuous 
BL, kin, KD, EMAX kdis 
Abbreviation: BSAP=serum bone-specific alkaline phosphatase; CTX=serum 
collagen type 1 cross-linked C-telopeptide; P1NP=serum type-1 procollagen N-
terminal; BL=baseline BMD; kin=rate of BMD formation; KD=dissociation 




4. Population PK-PD Models of Blosozumab Results 
 
4.1. PK Data Disposition 
There were a wide range of samples that covered the absorption, 
distribution and elimination phases of the blosozumab PK profile.  The dose 
ranges that were tested were wide and ranged from single dose 7.5mg IV to 
750mg Q2W IV. The wide range of doses tested allowed for better 
characterization of the PK and PD profiles. In particular, the IV regimens 
allowed for estimation of the bioavailability of blosozumab and revealed the 
non-linear kinetics of the drug. Table 3 summarized the baseline 





Table 3 Demographic and baseline characteristics of subjects 
included in the population pharmacokinetics model 
Study 1 2 3 4 All 
N 48 18 44 115 225 
Continuous Covariates (Mean (SD)) 
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Categorical Covariates (N) 
Race 
        African American 2 - - - 2 
   Western Asian - - 8 - 8 
   Caucasian 45 - 36 65 146 
   Japanese - 18 - 50 68 
   Native American 1 - - - 1 
Abbreviation: N=number of subjects; BMI=body mass index; BSAP=serum bone-specific 














4.2. Final PK Model  
The final PK model was a two-compartment model with first-order SC 
absorption. Blosozumab was assumed to be eliminated from the central 
compartment. The elimination of blosozumab is modeled using a parallel 
linear and non-linear clearance. This non-linear portion was modeled 






   E.16 
 
where CLnonlinear  represents the capacity limited clearance, CLmax  the upper 
limit of the elimination process, C50 the affinity constant and Conc the drug 
concentration. 
The total clearance of the drug is thus a combination of the non-specific linear 
component and a capacity-limited, target-mediated non-linear component 
(E.17).  
 𝐶𝐿𝑡𝑜𝑡𝑎𝑙 = 𝐶𝐿𝑙𝑖𝑛𝑒𝑎𝑟 + 𝐶𝐿𝑛𝑜𝑛𝑙𝑖𝑛𝑒𝑎𝑟   E.17 
 
The non-linearity is most obvious in the higher doses of the IV 
administration arms, where the concentration time profile informed the 
elimination process of the drug following IV infusion. Compared to the SC 
administration, competing absorption and elimination processes were 
confounded and the observed concentration-time profiles appeared to decline 
in a monophasic fashion. Generally, drugs can be removed from the body 
through renal excretion and destruction by metabolism. Blosozumab is an IgG 
antibody that has a large molecular size of approximately 150kDa. Therefore, 
it is expected that very little intact blosozumab molecule can pass through the 
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renal filtration and be excreted in urine. In addition, there are neonatal Fc 
receptor (FcRn) expressed in the human renal glomerular epithelial cells that 
could potentially bind and reabsorb filtered IgG
92.
 Instead, elimination of 
antibodies is normally via catabolism. Typical IgG molecules have a serum 
half-life of about 23 days and elimination is subjected to influence by 
concentration
93.
 Besides the non-specific protein catabolism, blosozumab 
concentration can also be affected by binding to its target, where the process is 
often limited by the availability of the target, and contributes to the non-linear 
kinetics.  
After an IV dose, blosozumab concentration followed a bi-exponential 
decline from the Cmax, which was achieved at the end of the infusion. In the 
SC cohort, due to the slow drug absorption, the median tmax was approximately 
3 to 6 days postdose. The PK of blosozumab demonstrated clear nonlinearity, 
evident by the changing slope of the terminal phase over time (Figure 6).  This 
nonlinear PK appeared to be drug concentration-dependent, where at higher 
dose levels, there was decreased clearance and increased terminal t1/2.  
The model adequately described blosozumab disposition 
characteristics.  Generally, precision around PK parameter estimates was good 
as evident by low %SEEs (standard error of estimate) not exceeding 30% and 
tight 95% CIs (confidence interval).  The PK parameter estimates from the 
final model, inclusive of covariate effect, are summarized in Table 4. Figure 5 
illustrates a good fit between the population and individual predictions against 
the observations; also residuals against model predictions did not show any 
obvious deviations. There are two samples with individual weighted residual 
(iWRES) more than 10 (Figure 5, lower left corner). Visual inspection of these 
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two records did not show any anomalies and conditional weighted residuals 
profiles did not show any obvious trends of model misspecification (Figure 5, 
lower right corner). 
A visual predictive check (VPC) comparing observed serum 
blosozumab concentrations versus time profiles against the posthoc model-
predicted profiles showed that the model adequately described the data across 




 percentile of the model 
predictions were in close agreement with the observations, suggesting that the 
structural model and the variability estimates were appropriate.  The majority 
of observed blosozumab concentrations were within the 90% prediction 
intervals from the population PK model.   
Two SC formulations were used in the clinical trials to date.  There 
appears to be slight differences in the bioavailabilities of these two 
formulations. The absolute bioavailability for SC formulations was estimated 
to be approximately 54% (formulation 1, dosing solution concentration ~ 30 
mg/mL, used in Studies 1 and 2) and 69% (formulation 2, dosing solution 
concentration ~ 60 mg/mL, used in Studies 3 and 4), respectively. The 
bioavailability of blosozumab is consistent with typical antibodies where most 
have reported bioavailabilities of between 50 and 100%
93
. The factors that 
affects the amount of drug absorbed varied, affected by the amount of 
presystemic degradation, molecular size and the limit of injection volume that 
is allowed due to associated pain. Formulation 2 allows for the more 
molecules to be packed into a smaller injection volume and demonstrated 
better bioavailability and possibly better pain tolerability since the injection 
volume is reduced. 
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The t1/2 was calculated using the empirical Bayes estimates from the 










∙ (𝑘23 + 𝑘23 + 𝑘 − √(𝑘23 + 𝑘23 + 𝑘)2 − 4 ∙ 𝑘32 ∙ 𝑘 
 
 
Since blosozumab follows concentration-dependent PK, the terminal half-life 
(t1/2) varies with drug concentration, which was expected to be between 
approximately 3 days (when C50 >> Conc and hence 𝐶𝐿𝑡𝑜𝑡𝑎𝑙 ≈ 𝐶𝐿𝑙𝑖𝑛𝑒𝑎𝑟 +
𝐶𝐿𝑛𝑜𝑛𝑙𝑖𝑛𝑒𝑎𝑟) and 14 days (when C50 << Conc and hence 𝐶𝐿𝑡𝑜𝑡𝑎𝑙 ≈ 𝐶𝐿𝑙𝑖𝑛𝑒𝑎𝑟).
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Table 4 Pharmacokinetic and Covariate Parameters in Final 
Population Model 






Parameter Description (%SEE; and 95% CI) (%SEE)a 
Mean (%SEE; and 95% 
CI) 
Absorption rate constant (Ka, 1/h) 0.00697 40.10% 0.00698 
     Parameter for  (4.33%; 0.00641, 0.00768) (16.8%) (0.0438%, 0.00643, 0.00763) 
Constant clearance (CL, mL/h) 8.82 32.90% 8.88 
 
(5.24%; 8.09, 9.77) (22.8%) (0.0596%, 7.95, 10.1) 
Saturable clearance (CLSAT, mL/h) 122 26.00% 127 
 
(11.0%; 102, 150) (15.7%) (0.124%, 102, 166) 
Inter-compartmental clearance (Q, mL/h) 16.8 - 16.8 
 
(5.20%; 15.5, 18.4) 
 
(0.0537%, 15.1, 18.7) 
Michaelis Menten constant (C50, nM) 12.8 - 12.5 
      (15.5%; 9.76, 16.6)  (0.166%, 8.39, 16.7) 
Central volume (V, mL) 2520 13.40% 2520 
 
(1.73%; 2430, 2610) (24.9%) (0.0176%, 2430, 2600) 
 Peripheral volume (V2, mL) 1440 19.60% 1440 
 
(3.84%; 1330, 1540) (40.3%) (0.0404%, 1330, 1560) 
Absolute bioavailability (%) 
  
      F for formulation 1 54 - 53.9 
 
(6.17%; 47.7, 61.5) 
 
(0.0636%, 47.1, 60.5) 
     F for formulation 2 69.1 - 69.2 
 
(3.30%; 65.8, 73.9) 
 
(0.0348%, 64.5, 74.0) 
  Covariate -  BW on CLSAT 
b
 0.0157 - 0.0156 
 
(13.7%; 0.0113, 0.0201) 
 
(0.139%, 0.0115, 0.0200) 
  Covariate -  BW on V and V2 
c
 0.0108 - 0.0108 
   (10.9%; 0.00843, 0.0132)   (0.112%, 0.00853, 0.0132) 
Residual Error (Proportional, %)
d
 |  (Additive, nM)
e
                                          
     Study 1 8.43% (9.59%) | 2.39 (40.4%) 
      Study 2 23.4% (11.2%) | 2.40 (74.9%) 
      Study 3 6.18% (19.4%) | 2.40 (38.8%) 
      Study 4 11.8% (25.1%) | 6.83 (42.0%) 
 Abbreviations:  %SEE = relative standard error of estimation; “-” = fixed to zero; BW= body 
weight; C50 = Michaelis-Menten constant; CI = confidence interval; CL = systemic 
clearance of drug; CL/F = apparent systemic clearance of drug; CLSAT = saturable 
systemic clearance; Ka = absorption rate constant; Q = distribution clearance. 
a
 Reported as %CV, calculated by equation: 100 ∙ √𝑒𝑂𝑀𝐸𝐺𝐴(𝑁) − 1, where OMEGA(N) is 
the NONMEM output for the between-subject variability of the Nth parameter. 
b
 CLSAT = 122 * [1+0.0157*(BW-61.5)], where median BW=61.5kg. 
c
 Vi = typical value Vi* [1+0.0108*(BW-61.5)], where median BW=61.5kg. where Vi is V 
or V2 
d
 Reported as %CV, calculated by equation:  100 ∙ √𝑆𝐼𝐺𝑀𝐴(𝑁), where SIGMA(N) is the 
NONMEM output for the proportional residual error for the Nth study. 
e
 Reported as nM, calculated by equation:  √𝑆𝐼𝐺𝑀𝐴(𝑁), where SIGMA(N) is the 
NONMEM output for the additive residual error for the Nth study. 
f




Abbreviations: iWRES = individual weighted residual. 
 













Open blue circles represent the observed blosozumab concentration. Blue band represents the 
90% prediction interval from the model. Solid black band represents the median prediction. 
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4.3. PK Model Covariate Analysis 
In summary, only body weight was found to be an important patient 
factor that impact the distribution and elimination of blosozumab. Of note, 
since body surface area (BSA) and body weight are both size descriptors so 
they are confounding factors. The change in OFV and reduction in inter-
individual variability for BSA as a covariate on clearance were consistently 
lower than those models where body weight was applied on clearance. 
Therefore, only body weight was retained as a significant covariate on the 
clearance and volumes of distribution of blosozumab.   
In addition, since blosozumab is a large molecule, its elimination is 
anticipated to be via normal protein catalysis and is not expected to be 
dependent on renal function for excretion.  Therefore, the CL of blosozumab is 
unlikely to be closely associated with the renal function of the patient and thus 
renal function was not tested as a covariate. 
Prior bisphosphonate exposure (BP) did not appear to have an effect on 
the PK of blosozumab. It was observed that the PK profiles overlapped 
between naïve and BP subjects given the same doses. 
Anti-drug antibodies were analyzed by a validated screening assay and 
positive samples were then titrated to report a titer value. 
4.3.1. Effect of Body Weight on Blosozumab Clearance 
A statistically significant association was found between body weight 
and blosozumab CLSAT.  Mean population blosozumab CLSAT was 
estimated to be 122 ml/L for a 61.5kg PMP woman. Every one-kilogram 
increase in body weight increased the CLSAT by 1.57%. The estimated 
interindividual variability for CLSAT was 26.0%.  Objective function 
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decreased by 44.4 points (1 degree of freedom, p<.001), accompanied by a 5% 
reduction in interindividual variability, down from 31%.   
4.3.2. Effect of Body Weight on Blosozumab Volumes of Distribution 
A statistically significant association was found between body weight 
and blosozumab V and V2.  Mean population blosozumab V and V2 were 
estimated to be 2520 ml and 1440 ml for a 61.5kg PMP woman respectively. 
Every one-kilogram increase in body weight increased the volume of 
distributions (V and V2) by 1.08%. The estimated interindividual variability 
for V and V2 were 13.4% and 19.4%, respectively.   
4.4.3. Effect of Anti-Drug Antibody (ADA) on Blosozumab  
Only 11% of all samples collected for immunogenicity analysis were 
tested positive for the presence of anti-drug antibody. Only one subject (study 
4, 180mg Q2W SC) had obvious anti-drug antibody effect on the blosozumab 
exposure and this subject was excluded from the analysis. This subject had 
reduced blosozumab exposure, low BMD, and had a positive ADA screening 
titer at baseline (1:10).  Review of this patient suggested no adverse systemic 
effects in this patient.  Screening ADA status (yes/no) [categorical] and the 
titer [continuous] were investigated as time-varying covariates to explore if 
they had any effect on the PK parameters. Adding ADA as covariate to CL 
and CLSAT reduced the objective function values (about 17 points) but not 
the inter-individual variability on the PK parameters. There was no strong 
evidence to suggest that ADA had any significant effect on the PK of 
blosozumab. 
4.4. BMD Data Disposition 
The final dataset for PD analyses contained a total of 1851 BMD 
samples from 152 patients who received blosozumab or placebo treatment in 
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study 4. Table 5 summarized the demographics and baseline characteristics of 
the patients included for in the BMD analysis. Blosozumab was administered 
for one year and the subjects were observed for an additional one-year post 
treatment termination. The second year follow-up observation period allowed 
for the estimation of rate of return to baseline. There were approximately 20% 
of the data between 15 and 24 months of the study period and this provided 
sufficient information for good data fitting. Blosozumab treatment for 12 
months resulted in significant increases in lumbar spine and total hip BMD.  
During the follow-up phase (12-24 months), lumbar spine BMD percent 
change from baseline decreased for all blosozumab treatment groups.  The 
percent change from baseline BMD at 24 months was significantly different 
from baseline and placebo for the blosozumab treatments, suggesting that 
although the treatment effect peaked at the end of the 12-months treatment, the 
bone formation effect persisted for more than one year as the BMD returned 
towards baseline. In addition, there were small declines from baseline in both 
the lumbar spine and total hip BMD in the placebo cohort at the end of 24 
months, suggesting a worsening of the osteoporosis disease state during the 










Table 5 Demographic and baseline characteristics of subjects 










Abbreviation: N=number of subjects; IV=intravenous infusion; 
SC=subcutaneous injection; BMI=body mass index; BSAP=serum 
bone-specific alkaline phosphatase; CTX=serum collagen type 1 







Continuous Covariates (Mean (SD)) 
   Age (years) 65.3 (8.32) 
   BMI (kg/m
2
) 23.9 (4.32) 
   Weight (kg) 58.5 (12.3) 
   BSAP (μg/L) 35.5 (13.6) 
   CTX (ng/mL) 0.391 (0.225) 
   Osteocalcin (ng/mL) 26.4 (9.92) 
   P1NP (μg/L) 61.5 (23.6) 
  Sclerostin (nM) 0.135 (0.116) 
  Lumbar Spine BMD (g/cm
2
) 0.743 (0.056) 
 Total Hip BMD (g/cm
2
) 0.747 (0.121) 
Categorical Covariates (N) 
Race 
    African American 1 
   Caucasian 87 
   Japanese 64 
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4.5. Final BMD Model  
The structural PD base model is an indirect-response pharmacological 
model that describes the exposure-response relationships of blosozumab 
concentration, exerting a stimulatory effect on the formation of BMD (Figure 
4).  A linear slope was estimated to describe the deterioration of BMD over 
time. Japanese patients were found to have lower baseline BMD values than 
non-Japanese patients in both lumbar spine and total hip BMD. This difference 
in the BMD levels between Japanese and non-Japanese subject is therefore 
included into the base model. A pseudo target-engagement describing free 
target and blosozumab-target complex was used to link the PK and PD 
models. Of note, the 2 compartments representing free target and blosozumab-
target complex are both with theoretical quantities, inform the percentage of 
target in free or drug-bound forms, and are comparable to those in a receptor 
occupancy model, i.e., the sum of their quantity is always 1.   
Table 6 summarizes the parameter estimates from the population PD 
model. The mean baseline lumbar spine BMD were 0.711 g/cm
2
 and 0.767 
g/cm
2
 for Japanese and non-Japanese subjects respectively; while the mean 
total hip BMD were 0.653 g/cm
2
 and 0.805 g/cm
2
 for Japanese and non-
Japanese subjects respectively. The inter-individual variability for lumbar 
spine and total hip baseline BMD were 6.53% and 12.8%. The total hip BMD 
measurements were more variable though the variability was small in general. 
The difference in the BMD between Japanese and non-Japanese subjects could 
be due to the body mass differences in the two groups. Japanese subjects on 
the average weights about 15.2 kg lesser than the non-Japanese subjects and 
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Bone turnover was assumed to remain at a steady state with turnover 
rate that is controlled by the zero-order rate of bone formation, 𝑘𝑖𝑛, and the 
first-order rate of bone destruction, 𝑘𝑜𝑢𝑡. The 𝑘𝑖𝑛 values estimated for lumbar 
spine BMD and total hip BMD were 0.340 and 0.0156 g/cm
2
/week, 
respectively, suggesting that the bone turnover is approximately two-fold 
higher in lumbar spine that in total hip. This faster bone turnover rate dictates 
that under the same regimen, the drug effect in lumbar spine is achieved faster 
than in total hip and for the same reason, with the discontinuation of the 
treatment, the BMD loss in lumbar spine is faster than in total hip. 
The rate of disease progressions estimated for lumbar spine and total 
hip BMD were 0.0121 g/cm
2
/year and 0.00780 g/cm
2
/year, respectively, 
suggesting that bone loss is faster in lumbar spine compared with total hip. 
The estimated disease progression was limited by the two-year placebo data 
that were collected in blosozumab clinical study 4 and a parsimonious linear 
rate of decline. Nonetheless, the rates of disease progression added to the 
model improved the overall model fit and provides an assessment of the rate 
of decline of BMD over time. 
Correlation was identified between baseline lumbar spine BMD and 
baseline total hip BMD in both Japanese and non-Japanese subjects.  
Similarly, correlation between the maximum BMD responses in lumbar spine 











(%SEE; and 95% CI) (%SEE)a Mean (%SEE; and 95% CI) 
BMD baseline (g/cm2) 
  
      Lumbar spine (Japanese)  0.711 6.53% 0.710 
 
(0.864%; 0.699, 0.723) (13.8%) (0.00897%; 0.699, 0.724) 
     Lumbar spine (non-Japanese)  0.767 6.53% 0.767 
 
 (0.932%; 0.756, 0.778) (13.8%) (0.00650%; 0.757, 0.776) 
     Total hip (Japanese)  0.653 12.80% 0.652 
 
(1.61%; 0. 633, 0.674) (14.4%) (0.0180%; 0. 627, 0.675) 
     Total hip (non-Japanese)  0.805 12.80% 0.804 
 
(1.70%; 0.783, 0.826) (14.4%) (0.0119%; 0.784, 0.822) 








Emax of BMD increase (%) 
   
     Lumbar spine 20.5 24.80% 21.5 
 
(7.02%; 17.9, 24.0) (32.1%) (0.147%; 17.7, 31.5) 
     Total hip 9.27 48.70% 10.1 
 
(15.1%; 6.96, 13.2) (39.9%) (0.249%; 7.02, 17.3) 
Correlation coefficient between  - 0.879 - 




BMD Production rate (Kin, g/cm2/week) 
   
     Lumbar spine 0.034 20.9% (74.8%) 0.0333 
 
(12.1%; 0.0270, 0.0427) 
 
(0.173%; 0.0189, 0.0437) 
     Total hip 0.0156 45.3% (55.6%) 0.0154 
 
(15.2%, 0.0110, 0.0207) 
 
(0.226%, 0.00784, 0.0220) 
Disease progression (BMD loss, g/cm2/year)  
   
     Lumbar spine -0.0121  161% -0.0129  
 
(38.2%; -0.0241, -0.00576 ) (52.0%) (0.483%; -0.00727, -0.0257) 
     Total hip -0.00780 115% -0.00801  
 
 (27.6%; -0.0130, -0.00344) (59.5%) (0.324%; -0.00285, -0.0134) 
Dissociation rate constant (Koff, 10-3/hr) 0.458 76.90% 0.556 
      (21.5%; 0.325, 0.711) (48.8%) (0.614%; 0.305, 1.56) 
Dissociation coefficient (KD, nM) 21.4  
22.6 
 
(22.9%; 13.2, 31.9) 
 
(0.278%; 12.8, 35.5) 
Residual Error (Proportional, %)b                                            
      Lumbar spine 2.05 (3.54%) 
      Total hip 1.39 (4.35%)   
Abbreviations:  %SEE = relative standard error of estimation; “-” = fixed to zero; BMD= bone 
mineral density.  
a
 Reported as %CV, calculated by equation:  100 ∙ √𝑒𝑂𝑀𝐸𝐺𝐴(𝑁) − 1, where OMEGA(N) is 
the NONMEM output for the between-subject variability of the Nth parameter. 
b
 Reported as %CV, calculated by equation:  100 ∙ √𝑆𝐼𝐺𝑀𝐴(𝑁), where SIGMA(N) is the 
NONMEM output for the proportional residual error. 
c
   1000 bootstrap analyses sampling original data with replacement. 
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Figure 7 illustrates the goodness-of-fit between the model the observed lumbar 
spine and total hip BMD and the model predictions. There was good 
agreement between the population and individual model predictions and the 
observed data.  Inspection of the residual errors also showed no obvious 
irregular trends. In general, the model can describe the data adequately. The 
precision of the parameter estimates was good as demonstrated by the low 
standard error of estimates (%SEE) (Table 6). 
To evaluate the performance of the final base population exposure-
BMD model, VPC was conducted by simulating 1000 replicates of the trials.  
Figure 8 and Figure 9 overlay the observed and model-predicted percent 
change of BMD from baseline (population median and 90% prediction 
intervals) for lumbar spine and total hip at each dose level in Study 4, 
respectively.  This VPC illustrates that the distribution of simulated BMD 
responses from the population BMD model is in agreement with observed 






Abbreviations: IWRES = individual weighted residual. 
Figure 7 Goodness-of-fit diagnostic plots of blosozumab final 
pharmacodynamics model. First and Second Row: 







Note: Open blue circles represent the observed BMD measurements. Solid and 




 percentiles of the 
observed BMD measurements. The red and blue shaded areas represent the 






 percentiles of the observed 
BMD measurements. 
Figure 8 Visual predictive check for the final Lumbar Spine BMD 











Note: Open blue circles represent the observed BMD measurements. Solid and 




 percentiles of the 
observed BMD measurements. The red and blue shaded areas represent the 






 percentiles of the observed 
BMD measurements. 
Figure 9 Visual predictive check for the final Total Hip BMD model. 
(A) Absolute value. (B) Percent change from baseline.  
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4.6. BMD Model Covariate Analysis 
For hypothesis generation purposes, a limited covariate search was 
conducted to identify potential factors that may influence BMD responses.  
The potential covariates evaluated include body weight, age, ethnicity, 
baseline BMD, baseline sclerostin level, and baseline values of major bone 
biochemical markers (P1NP, CTX, osteocalcin, and BSAP).  The impact of 
immunogenicity in the format of neutralizing antibody on bone formation 
activity was also evaluated.   
Body weight and baseline P1NP were identified to impact certain 
model parameters. However, it was determined that these factors were not 
considered to be clinically meaningful. Figure 10 shows the final base model 
and the final BMD model are equally good in predicting distributions of 
patient BMD responses in lumbar spine and total hip at week 52. Additionally, 
P1NP levels on the rate of BMD formation were limited to the overall 
turnover of the bone. This has limited effect on the overall formation of the 
BMD since both the rate of formation and destructions were elevated over the 
time course of observations. The drug and placebo effects (Emax, KD and 
disease progression parameter) were not meaningfully altered with different 
levels of baseline P1NP level. Adding body weight as a covariate to the 
baseline total hip BMD had little impact on reducing the inter-individual 
variability and will have little drug development usefulness since baseline 
BMD are controlled within the study inclusion/exclusion criteria. In summary, 
the final model that best describes the BMD observations did not include the 
effect of body weight on total hip BMD baseline and P1NP baseline level on 






Note: thick solid lines in the middle represent the median; box represents the 
inter-quantile range (IQR). black solid circles represent the data outside the 
1.5x IQR. 
 
Figure 10 The distribution of lumbar spine and total hip BMD 
percent change from baseline at 1-year observed in Study 
4 (Obs) or predicted with the Population BMD models 




5. System Pharmacology Model of Anti-Sclerostin 
Treatment Materials and Methods 
The purpose of the second part of the report was to integrate the 
sclerostin regulation mechanism on bone activities with a physiological-based 
bone remodeling mathematical model that accounts for the tight coupling of 
osteoblast and osteoclast actions
6
.  The kinetic profiles of the total and 
unbound sclerostin after anti-sclerostin therapy were characterized using 
target-mediated drug disposition (TMDD) model, based on the range of 
blosozumab and romosozumab doses available from published reports. The 
drug action of anti-sclerostin was then incorporated in the bone remodeling 
model through the unbound sclerostin control of osteoblasts and osteoclasts. 
The model was calibrated with blosozumab and validated with romosozumab 
using data on bone biomarkers temporal responses extracted from published 
clinical trials. The model was then further extended by integrating the BMD 
time course model through linking the osteoblast actions and bone formation 
rate. Similarly, the model parameters were calibrated and validated using the 
BMD observations from the blosozumab and romosozumab clinical trials, 
respectively.  
5.1. Bone Remodeling Model Background 
The bone remodeling model by Lemaire et al. forms the base structural 
model that describes the interactions between cellular bone interaction and 
how the cells change in response to perturbation
6,95–100
. The original model 
was developed to describe osteoblasts and osteoclasts regulation and 
interaction in bone remodeling process. The model was used to investigate 
different bone diseases and their possible therapeutic interventions by altering 
model components and extrapolating the results with osteoblast and osteoclast 
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changes. The model was successful in replicating the osteoblast and osteoclast 
responses (increased or decreased) in certain bone diseases, as caused by loss 
of estrogen in menopause and degradation by glucocorticoid for example, and 
made plausible predictions of the efficacies of potential anti-resorptive and 
anabolic bone therapies. The original Lemaire model was since adapted to 
describe different bone deficiencies with extension to quantify biomarkers, 
bone mineral density or bone volume changes in theoretical scenarios or 
calibrated with different osteoporosis treatments
90,96–99,101–103
. Of particular 
note, the University at Buffalo group adapted the original model, but used 
most parameter estimates as reported in original Lemaire paper, to describe the 
bone resorption marker responses after denosumab treatments
97,98
. More 
recently, the Metrum research group reported a systems pharmacology 
model
102
 and included sclerostin pathway in bone remodeling
90
, based on the 
original Lemaire model, but reparameterized extensively with additional 
components that included hypotheses of PTH intracellular signaling
104
 and  
calcium homeostasis
105
.   
In this project, we aim to extend the original model with the sclerostin 
regulation but keep only the most important components of bone remodeling, 
similar to the approach used by the University at Buffalo. This approach 
affords us the flexibility and options to then combine reported models, which 
are based on the original Lemaire model, into a single unified model that will 
allow predictions of treatment efficacies in combination therapies for bone 
diseases.    
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Important aspects of the model pertinent to the analysis of the 
sclerostin mechanism of action are described below and the full set of 
equations describing the extended bone remodeling model is in Appendix A.  
The cellular model composes of 3 distinct cellular groups namely the 
responding osteoblasts (ROBs), active osteoblasts (AOBs) and the active 
osteoclasts (AOCs). The model represents four major differentiation stages of 
the bone cells with two representing the cells of bone-forming osteoblastic 
lineage and two representing the cells of bone-resorbing osteoclastic lineage.  
The osteoblastic lineage cells are represented by two states (ROBs and 
AOBs) which were modeled as two differential equations (Section 5, E.25 and 
E.26). ROBs represent a diverse group of precursor cells that have the 
potential to develop into AOBs and carry out bone formation. The ROBs were 
assumed not to have direct involvement in bone formation but rather act as a 
precursor pool of cells that is subject to regulation and thus controls the input 
rate of AOBs. Physiologically, the ROBs represent the uncommitted 
progenitor cells of osteoblastic lineage that include myocytes, adipocytes and 
mesenchymal progenitors. TGF-β signals for the aggregation of the ROBs to 
the site of bone remodeling but prevents further maturation of the ROBs into 
AOBs. When the TGF-β signal diminishes as resorption activities decrease, 
inhibitory signals are removed allowing ROBs to proceed to differentiate into 
AOBs. The AOBs then carry out the bone forming responsibilities and after 
which the cells then differentiate into lining cells and osteocytes, or are 
destroyed via apoptosis. The osteoclastic lineage cells are similarly divided 
into two states, namely, the precursors and active osteoclasts (AOCs). The 
source of osteoclast precursors was assumed to be unlimited and only the 
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AOC was modeled as a differential equation (Section 5, E.27). The precursor 
osteoclasts under the influence of RANK-RANKL binding will differentiate 
into AOCs that carry out bone resorption. The AOCs break down bone matrix 
and release the TGF-β stored within the bone matrix. The AOCs then, under 
TGF-β feedback, are destroyed via apoptosis.  
The bone remodeling process is thus a tightly coupled process where 
osteoclastic and osteoblastic processes follow strict temporal regulation. 
Homeostasis is achieved via the RANK-RANKL-OPG axis and the TGF-β 
signaling. The AOBs express cell surface RANKL that binds to RANK on 
precursor osteoclasts and converts them into AOCs. On the other hand, the 
osteoclasts when breaking down the bone, release the TGF-β stored within 
bone matrix. The TGF-β was assumed to increase the recruitment of ROBs to 
the site of the bone remodeling but then block the ROBs from further 
differentiation into AOBs. The different TGF-β effect contributes to the 
temporal regulation whereby bone formation only begins after bone formation 
completes.  
Additionally, PTH is added as affecting the RANKL and OPG 
production through binding with PTH receptors on the ROBs and AOBs. PTH 
enhances RANKL but reduces OPG production. This effectively enhances the 
AOC level and leads to increased bone resorption. The current understanding 
of the PTH’s mechanism of action of bone formation and resorption is not 
entirely clear and this segment of the bone homeostasis model will need to be 
updated when more information becomes available.  
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This project extended the base model as described above by 
incorporating the PK of anti-sclerostin mAb drug treatment with its binding to 
sclerostin, and regulatory actions of sclerostin on osteoclasts and osteoblasts.  
5.2. Dataset and Model Description 
The data for building sclerostin regulation of bone remodeling was 
extracted from publicly available information in clinical reports of 
blosozumab and romosozumab. PK information for blosozumab were 
available in a poster presentation at 6
th
 Annual Meeting of American 
Conference of Pharmacometrics 2015 (ACoP6)
106
 and details of the model 
development and results were in population PK-PD analysis section of this 
report (Sections 3 and 4). However, mean PK profiles were not available 
publicly. PK information for romosozumab were reported in two journal 
articles
55,56
. The concentration-time profiles of romosozumab after single 
ascending doses of romosozumab were digitized to characterize the PK 
parameters. The non-compartmental PK parameters of romosozumab after 
multiple doses of romosozumab were used as comparison to assess the validity 
of the PK parameters.  
Total sclerostin levels following single and multiple doses of 
blosozumab administration in phase 1 and phase 2 clinical trials were 
reported
57,107
 and the data were digitized and used to develop the kinetics 
model of sclerostin levels. Sclerostin levels after romosozumab treatment were 
not available. 
Bone turnover markers of bone formation, specifically serum P1NP, 
and bone resorption, specifically serum CTX, were reported in two phase 1 





. The bone turnover markers were used to inform the 
anti-sclerostin treatment effect of the bone remodeling model. Graphical data 
were extracted using PlotDigitizer (version 2.6.3).   
The target-mediated drug disposition as well as the bone remodeling 
model with the sclerostin effect extension was estimated using Berkeley 
Madonna (version 8.0.1, University of California at Berkeley), utilizing 
simplex search algorithm based on least square minimization method 
implemented within the software. The Runge-Kutta integration algorithm 
(RK4) was used to solve the ordinary differential equations. The Berkeley 
Madonna code for the extended bone remodeling model is in Appendix D. 
Graphical results were plotted using either S-PLUS (version 8.2, TIBCO 





5.2.1. Mathematical Description of Target-Mediated Drug Disposition 
Kinetics 
A semi-mechanistic model was proposed to describe the kinetics of 
sclerostin levels following blosozumab treatment. The basic model structure 
describing the kinetics of blosozumab and sclerostin is illustrated in Figure 11. 
Blosozumab given subcutaneously into the interstitial layer will move into the 
vasculature through fluid convection exerted by the higher fluid pressure 
caused by the high concentration of drug at the site of drug administration. In 
the vasculature, blosozumab largely circulates in the serum because of its large 
molecular size. However, a small amount of the drug can distribute into the 
peripheral tissue through gaps and channels within the endothelial or be taken 
up through non-specific endocytosis. We assumed that limited blosozumab are 
distributed in the bone compartment and modeled the distribution of 
blosozumab as one general peripheral tissue compartment. The blosozumab 
concentration follows a two-compartment model as described in Section 3.2 
on the population PK model (Figure 3), where blosozumab follows first-order 
absorption after SC injection. Blosozumab distributes between serum and 
tissue compartments. The elimination of blosozumab follows that of the 
typical protein antibody which was modeled as two clearance pathways - one 
linear clearance and one saturable non-linear clearance. The saturable 
clearance is due to the binding of blosozumab to its target where the level of 
the target molecule can be limited. In this case, blosozumab binds to the serum 
sclerostin where the blosozumab-sclerostin complex is then internalized via 




Abbreviation: As.c = amount of drug in subcutaneous injection depot 
compartment; A = amount of drug in central compartment; At = amount of 
drug in peripheral compartment;  C = serum drug concentration; Ct = tissue 
drug concentration; Scl = serum unbound sclerostin concentration; Cplx = 
serum drug-sclerostin complex concentration; k = rate of drug elimination; 
ksyn = rate of sclerostin production;kdeg= rate of sclerostin elimination; kint= 
rate of drug-sclerostin complex internalization; Doses.c = subcutaneous drug 
administration; Int(t) = intravenous drug administration; V=central volume of 
distribution; V2=peripheral volume of distribution. 
Figure 11 Schematic representation of the blosozumab target-





Sclerostin is a soluble protein produced only by the osteocytes within 
the bone matrix
42
. The local level of sclerostin therefore determines the level 
of inhibition of bone formation. There is a strong correlation between serum 
sclerostin level and bone sclerostin level suggesting that the sclerostin 
molecule distributes between the serum and the bone matrix
108,109
. 
Furthermore, the bone is a densely vascularized structure with leaky sinusoidal 
capillaries that allows exchange of materials between the vasculature and the 
bone tissue
110
. When compared with normal control subjects, patients with 
sclerosteosis has undetectable levels of serum sclerostin, while patients with 
heterozygous deleterious sclerostin mutation has only half the normal level of 
serum sclerostin level
111
. This shows that the serum sclerostin level is a 
suitable surrogate (for bone sclerostin level) for predicting sclerosteosis 
disease severity with respect to sclerostin inhibition on bone growth. For 
model parsimony, only the serum sclerostin level is modeled and described by 
a turnover model with a zero order production rate and first order distribution 
rate. The level of serum sclerostin was then linked to bone remodeling model 
assuming that the serum sclerostin level is proportional to the bone sclerostin 
level.  
Blosozumab was assumed to only bind sclerostin in the vasculature 
and was thus limited by the serum sclerostin that is available for binding to the 
drug. Binding of blosozumab to sclerostin forms the drug-target complex that 
will then be eliminated. Removal of unbound serum sclerostin increases the 
fluid pressure which draws more unbound sclerostin from the bone into the 
serum. Hence, a decrease in the serum unbound sclerostin was assumed to 
cause a proportional decrease in the sclerostin in the bone matrix. 
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A quasi-equilibrium target-mediated drug disposition model was used 
to describe the kinetics of the drug and sclerostin.  It was assumed that the 
binding of drug to sclerostin occurred at a much faster rate (milliseconds) than 
the kinetics of the drug and target distribution and elimination (hours); 
therefore the binding and unbinding appears to be at a quasi-steady state for 
our modeling and simulation purposes. The binding and unbinding rate 
constants (𝑘𝑜𝑛 and 𝑘𝑜𝑓𝑓) were thus be collapsed into the dissociation constant 
(𝐾𝐷). 
 
simplified to  
where 𝐶 represents serum blosozumab concentration; 𝑆𝑐𝑙  represents serum 
unbound sclerostin concentration; and 𝐶𝑝𝑙𝑥 represents serum drug-sclerostin 
complex concentration. 
Equations E.19 to E.23 show the full set of equations that described the 
quasi-equilibrium TMDD model and the derivation of the equations are 
detailed in Appendix B. 
𝑑(𝐴𝑠.𝑐.)
𝑑𝑡




= 𝐼𝑛(𝑡) + 𝑘𝑎 ∙
𝐴𝑠.𝑐.
𝑉
− (𝑘 + 𝑘23) ∙ 𝐶 +  𝑘32 ∙
𝐴𝑡
𝑉


























where 𝐴𝑠.𝑐. represents the amount of blosozumab in the depot compartment; 𝐴 
represents the amount of serum blosozumab; 𝐴𝑡  represents the amount of 
blosozumab  in the peripheral compartment; 𝑆𝑐𝑙  represents the serum free 
unbound serum sclerostin concentration; 𝐶𝑝𝑙𝑥  represents the serum drug-
target complex; 𝑘𝑜𝑛  represents the binding constant and 𝑘𝑜𝑓𝑓  the unbinding 
coefficient of drug and target; 𝑘𝑠𝑦𝑛  and 𝑘𝑑𝑒𝑔  represent the synthesis and 
degradation of sclerostin, respectively, and 𝑘𝑖𝑛𝑡 represents the elimination of 
the drug-target complex; 
𝐷𝑜𝑠𝑒𝑠.𝑐.
𝐹
 represents the subcutaneous administration of 
blosozumab and F represents the absolute bioavailability; 𝐼𝑛(𝑡)  represents 
input rate of intravenous administration of blosozumab; and 𝑆𝑐𝑙0  represents 
baseline unbound sclerostin concentration. 
The TMDD model was fitted to publicly available sclerostin data from 
blosozumab trials
57,136
. The parameters related to the PK portion of the model 
were fixed to the population estimates reported in Table 4
106
. The TMDD 
model fitted with blosozumab was then used to inform the sclerostin kinetics 
in romosozumab. 
The concentration-time profiles of romosozumab after single dose SC 
and IV administration was reported previously
55
. The data were extracted and 
used to estimate the PK parameters related to romosozumab using the same 
PK model developed for blosozumab (Figure 3). The doses reported in 
literature were in mg/kg, but the average weights of the subjects were not 
available. For modeling purposes, it was assumed that the average weight of 
the subjects in each treatment arm was 70kg
112
. The single-dose romosozumab 
trial enrolled both healthy men and PMP women. PMP women generally 
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weigh less (average 60kg, Table 3) than men, but 70kg is a reasonable 
assumption for the dose cohort and was consistent with the doses of 70mg 
QM, 140mg QM/Q3M and 210mg QM/Q3M tested in the phase 2 
romosozumab trial. 
  Sclerostin kinetics was then linked to the bone remodeling model 
through the sclerostin effects on osteoblast and osteoclast actions.  
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5.2.2. Mathematical Description of the Bone Remodeling Model 
Figure 12 illustrates the schematic representation of the bone 
remodeling model with sclerostin regulation extension added. The equations 



















= 𝐷𝐶 ∙ 𝜋𝐿 −  𝐷𝐴 ∙ 𝜋𝐶 ∙ 𝐴𝑂𝐶 
E.27 
 
where 𝑅𝑂𝐵 is the responding osteoblasts; 𝐴𝑂𝐵 is the active osteoblasts;  𝐴𝑂𝐶 
is the active osteoclasts; 𝐷𝑅 is the differentiation rate of osteoblast 
progenitors; 𝐷𝐵 is the maturation rate of responding osteoblasts; 𝑘𝐵 is the rate 
of elimination of active osteoclasts; 𝐷𝐶  is the maturation of the osteoclast 
precursors; and 𝐷𝐴  is the rate of osteoclast apoptosis. The parameters that 
regulates the interactions of osteoblast and osteoclasts, as defined by Lemaire 
and colleagues (𝜋𝐶, 𝜋𝐿, and 𝜋𝑃)
6
 as well as the proposed sclerostin regulation 
of the bone remodeling process  (𝜋𝑆𝑅, 𝜋𝑆𝐵, 𝜋𝑆𝐿, and 𝜋𝑆𝑂) are further described 
below (Sections 5.2.2.1 to 5.2.2.7).  
5.2.2.1. TGF-β regulation 
𝜋𝐶 is the TGF-β feedback upon receptor binding. It was assumed that 
the TGF-β kinetics proceeds at a much faster rate than the cellular changes. 
The TGF-β levels, on the time-scale of cellular changes, are therefore at steady 
state and are proportional to the number of osteoclasts. TGF-β was thus not 
modeled as a separate compartment. Instead,  𝜋𝐶 is a function of the change in 








where 𝐶𝑠  is the value of AOC to get half differentiation flux; 𝑓0 is a fixed 
proportion as defined in Lemaire et al., 2004
6
. 
The release of TGF-β from the bone matrix as osteoclasts break down 
the bone inhibits further resorption action from the AOCs. This self-regulation 
is mathematically instituted by increasing the osteoclast elimination 𝐷𝐴 ×
𝜋𝐶  × 𝐴𝑂𝐶. TGF-β was assumed to have distinct effects on ROBs and AOBs. 
The preosteoblastic cells are recruited and then flow into the ROB 
compartment by 𝐷𝑅 × 𝜋𝐶 . TGF-β, on the other hand, prevents the maturation 
of the preosteoblasts into AOB until the bone resorption process completes. 
Thus there is an inverse relationship between osteoblast maturation and TGF- 




5.2.2.2. RANK-RANKL-OPG regulation 
πL is the RANKL regulation of the osteoclast maturation. RANKL is a 
cell surface molecule on osteoblasts. The number of RANKL is, therefore, 
limited by the cell membrane carrying capacity and the upper limit of RANKL 
production is set at KPL=3 x 10
6
 per cell. The RANKL competes with OPG 
for binding with RANK. The binding (k3) and unbinding (k4) of RANKL and 
RANK to form RANKL-RANK complex, and the binding (k1) and unbinding 
(k2) of OPG and RANK to form OPG-RANK complex were assumed to occur 
at a much faster rate as compared with cellular changes, and that the species 
(RANKL, OPG, RANK) are at a quasi-steady state. The RANK receptor 
occupancy at quasi-steady state is as (E.29) and the derivation of the equation 
as per Lemaire et al.
6

















5.2.2.3. PTH regulation 
𝜋𝑃  is the PTH regulation of RANKL and OPG production. PTH 
increases the RANKL and decreases OPG production. This results in an 
overall increase in osteoclast activation and bone resorption level. The model 
is thus not able to describe the intermittent PTH treatment that will increase 
bone formation
113,114
.  This limitation will need to be further evaluated. But for 
our purpose it is not anticipated to affect sclerostin mechanism of action 
because sclerostin was assumed to act directly on the cells and not through 
PTH. The same parameterization and parameter values, per the original bone 
remodeling model
6
, for 𝜋𝑃 was used and the PTH level was kept constant.  
𝜋𝑃 =
𝑃𝑇𝐻
𝑃𝑇𝐻 + 𝑃𝑆 
 where, 𝑃𝑇𝐻 = 3.6nM and 𝑃𝑆 = 150nM  
      = 0.0234 E.30 
5.2.2.4. Sclerostin Regulation 
Sclerostin is mainly secreted by the osteocytes embedded in the bone 
matrix as a potent bone formation inhibitor
111
. The temporal changes in 
sclerostin will subsequently affect the downstream Wnt pathway regulations 
and have differential effects on osteoblasts and osteoclasts. Although 
osteocytes are the main contributor to the circulating sclerostin levels, 
temporal changes in the osteocyte numbers were not considered in the model. 
Osteocytes are the most common bone cells and make up more than 95% of all 
bone cells
23,115
. The average life span of the osteocytes goes beyond 20 
years
116,117
. Therefore, the number of osteocytes can be assumed to remain 
relatively constant during the period of clinical experiments and thus 
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osteocytes are not modeled as a compartment. The temporal changes in the 
sclerostin levels were assumed to be independent of osteocytes in the current 
model and is produced with a zero-order rate and eliminated with a first-order 
rate (Figure 11). The modeling of the kinetics of sclerostin is described in 
section 6. 
The effect of sclerostin was added at four intersections: namely, on the 
maturation of ROBs into AOBs, on the apoptosis of AOBs, on the RANKL 
levels and, on the OPG levels. Activating and repressing actions of sclerostin 
were introduced to the model using Hill functions E.31 and E.32 respectively. 












where 𝜋𝑎𝑐𝑡𝑖𝑣𝑎𝑡𝑜𝑟  represents the stimulatory effect of sclerostin; 𝜋𝑟𝑒𝑝𝑟𝑒𝑠𝑠𝑜𝑟 
represents the inhibitory effect of sclerostin; 𝛽  represents the maximum 
response and 𝛿 represents the sclerostin level needed to attain half maximum 
response; 𝑆𝑐𝑙 represents the concentration of the unbound sclerostin in serum. 
5.2.2.5. Sclerostin regulation on ROB maturation 
𝜋𝑆𝑅  is the sclerostin regulation of ROB maturation. Sclerostin is a 
repressor for AOB maturation
118–120
. When anti-sclerostin therapy is given, 
this inhibition is relieved and more ROBs differentiates into AOBs. This 
corresponds to increasing the removal of the precursor ROBs as the active 
osteoblast numbers builds up. An inhibitory relation (E.32) between sclerostin 
effect was added to the flux of ROBs maturating into AOBs given by 𝜋𝑆𝑅 ×
𝐷𝐵
𝜋𝐶∙
∙ 𝑅𝑂𝐵 .  Adding this signal rapidly increases the number of AOBs but 
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depletes the ROB pool. This causes a reduction in AOB numbers in later time 
points as the depleted ROB needs time to replenish. This is consistent with the 
observed bone formation marker turnover following repeated doses of anti-
sclerostin treatments. There was attenuation in the maximum response in 
BSAP, P1NP and osteocalcin following repeated dosing, where the bone 




5.2.2.6. Sclerostin regulation on AOB apoptosis 
𝜋𝑆𝐵  is the sclerostin regulation of the AOB apoptosis. In vitro 
experiments demonstrated that sclerostin accelerated the apoptosis of 
osteoblasts
120
. Sclerostin was shown to disrupt the various growth factors that 
are essential to the survival of osteoblasts and hasten the apoptosis.  An 
activating hill function, 𝜋𝑆𝐵 (E.31), was added to the 𝑘𝐵 term to increase the 
removal of AOB when sclerostin levels increase, given by 𝜋𝑆𝐵 × 𝑘𝐵 ∙ 𝐴𝑂𝐵. 
5.2.2.7. Sclerostin regulation on AOC 
The effect of sclerostin on osteoclasts is more complex and not entirely 
clear. In mice experiments, an increase in sclerostin levels led to an increase in 
RANKL production, which was then followed by an increase in osteoclastic 
bone resorption
121,122
. Conversely, when anti-sclerostin treatment was given, it 
reduced sclerostin levels, and the Wnt signaling pathway became uninhibited 
and downstream signaling enhanced. RANKL production was reduced and 
bone resorption was inhibited. 𝜋𝑆𝐿  , an activating Hill function, is the 
sclerostin regulation of RANKL level. Additionally, OPG production was 
lowered in β-catenin knock-out mice46, suggesting that up-regulating Wnt-
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signaling would instead increase OPG expression. 𝜋𝑆𝑂  , a repressor Hill 
function, is the sclerostin regulation of the OPG level. 
5.2.2.8. Biomarker Responses 
P1NP and CTX are the bone turnover biomarkers that closely relate to 
the activity of the osteoblast bone formation and osteoclast resorption activity 
respectively
123
. The percentage change from baseline of P1NP and CTX were 
assumed to vary proportionally with the normalized cell numbers. The percent 
change from baseline (%CFB)  in AOB and AOC were equated to the  percent 
change from baseline  (%CFB)  in P1NP and CTX, respectively (E.33 and 
E.34).  
 











where AOB represents active osteoblast; AOBb represents pretreatment active 
osteoblast baseline; AOC  represents active osteoclast; and AOCb  represents 
pretreatment active osteoclast baseline. 
All other parameters were fixed as previously reported
6
. The 
parameters related to sclerostin’s control of the bone cell interaction were 
estimated using the P1NP and CTX profiles reported in blosozumab clinical 
reports
57,59
. 𝑅𝑂𝐵𝑠𝑠 , 𝐴𝑂𝐵𝑠𝑠  and 𝐴𝑂𝐶𝑠𝑠  are the pretreatment baseline, steady 
state, ROB, AOB and AOC numbers. The values are fixed to the steady-state 
values. The 𝐴𝑂𝐶𝑠𝑠 was fixed to the 9.127 x 10
-4
 pM while 𝐴𝑂𝐵𝑠𝑠, 𝑅𝑂𝐵𝑠𝑠 and 
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constants to function function 
Abbreviation: AOB=active osteoblast; AOC=active osteoclast; CTX= serum type I C-terminal 
procollagen; DA=rate of osteoclast apoptosis caused by TGF-β; DB=rate of responding 
osteoblast differentiation; DC=rate of osteoclast precursor differentiation; DR=rate of 
osteoblast progenitor differentiation; kb=rate of elimination of active osteoblast; 
OPG=osteoprotegerin; P1NP=procollagen type I N-terminal propeptide; PTH=parathyroid 
hormone; RANK=Receptor activator of nuclear factor κ-B; RANKL=RANKL ligand; 
ROB=responding osteoblast, Scl=sclerostin. 
 
Figure 12 Schematic representation of the bone remodeling model 


















5.2.3. Mathematical Description of the Bone Mineral Density Model 
The primary end-point for phase 2 clinical trials in the treatment of 
osteoporosis is increase in BMD. BMD is currently used as diagnostic 
marker for determining osteoporosis and is highly predictive of fracture 
risk
124
. Two bone sites of interest in particular, lumbar spine and total hip, 
are indicative of the respective risk in spinal and hip fracture which are of 
clinical importance. 
An indirect response model forms the structural base for the BMD 
model in the bone homeostasis model. Instead of using the pseudo-drug-
target complex as a driving force to increase the bone formation rate, as in 
the population PK-PD model; AOB was used to affect the bone formation 
and AOC was used to affect the bone destruction. A power model that 
scales the steepness of the response was used to link the cellular component 
of the bone homeostasis model to the BMD models
90,103
. Lumbar spine and 
total hip BMD were modeled separately and parameters were estimated 
using the clinical observations from phase 2 blosozumab trial
59
.   
 The AOB was used to drive the increase in the BMD production 
rate. However, the osteoblast signal increases rapidly and then attenuates 
during the treatment period. This suggests that there is a delay between the 
increase in bone formation marker and the building of BMD. This is 
expected as the BMD accretion required that the osteoblasts produce and 
secrete the unmineralized bone matrix and then calcify it subsequently to 
form the mineralized bone matrix, which take a considerable amount of 
time. The average duration of a basic multicellular unit (BMU), which 




followed by osteoblasts filling the gaps with new bone materials trailing at 
the back, is between two to eight months, suggesting that bone formation 
takes roughly the same amount of time to be completed
125,126
. To account 
for the delay between the osteoblast formation and the BMD increase, an 
effect compartment was added to model this delay between osteoblast 
response and BMD increase (E.38). 
 
Abbreviation:  AOB = active osteoblasts; AOC = active osteoclasts; 
BMD = bone mineral density; kinBMD=rate of BMD formation; 
koutBMD=rate of BMD destruction 
 
Figure 13 Schematic representation of the bone mineral density 























where 𝐸𝑓𝑓𝑒𝑐𝑡  represents transit component that delays the effect of 
osteoblasts on BMD formation rate constant, 𝑘𝑖𝑛𝐵𝑀𝐷 represents the rate of 
BMD production, 𝑘𝑜𝑢𝑡𝐵𝑀𝐷  represents the rate of BMD resorption,  𝐴𝑂𝐵𝑏 
represents the pretreatment baseline value of AOB, 𝐴𝑂𝐶𝑏  represents the 
pretreatment baseline value of AOC, 𝛾𝑘𝑖𝑛  represents the coefficient that 
regulates effect of AOB and 𝛾𝑘𝑜𝑢𝑡 represents the coefficient that regulates 







6. System Pharmacology Model of Anti-Sclerostin 
Treatment Results 
6.1. Anti-Sclerostin mAb Target-Mediated Drug Disposition 
6.1.1. Blosozumab TMDD model 
Only mean sclerostin profiles after single and multiple doses of SC and 
IV blosozumab
57,136
 and population PK model parameter estimates
106
 were 
available in the literature. Due to the lack of meaningful blosozumab PK 
profiles, simultaneous estimation of all the TMDD model parameters was not 
possible. Instead, the PK-related parameters ( 𝑉 , 𝑉2 , 𝐶𝐿 , 𝑄 , 𝑘𝑎 , 
𝐹 [Biovailability]) were fixed to the values reported106; and only sclerostin-
related parameters (𝑘𝑑𝑒𝑔  [degradation rate of sclerostin], 𝑘𝑖𝑛𝑡  [rate of drug-
target complex internalization], 𝐾𝐷 [binding constant], and baseline sclerostin 





, 0.362 pmol/ml and 0.259 pmol/ml, respectively. Serum 
sclerostin levels increased following blosozumab administration
57,136
, which 
confirms target engagement of blosozumab, based on the assumption that 
binding of sclerostin by the antibody reduces the sclerostin clearance and 
thereby increases total sclerostin levels in the blood stream. The increase in 
total sclerostin levels was dose-dependent with higher blosozumab doses 
resulting in a larger increase in the sclerostin levels and the increase was 
generally maintained during the treatment phase. After blosozumab was 
discontinued, sclerostin levels rapidly fell then maintained around 
pretreatment baseline through the rest of the observation period. It was 
reported that the individual baseline sclerostin values were variable. The 
750mg IV Q2W blosozumab regimen had a higher mean baseline compared 
with other dose arms but showed a lower change from baseline values 
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compared to the 540mg IV Q4W blosozumab regimen. This affected the 
change from baseline sclerostin levels not following the dose levels and dose 
intervals rank order
57
. Including this 750mg IV Q2W dose arm in the TMDD 
model resulted in resulted in a worse fit of the model. Therefore, the 750mg 
IV Q2W dose arm from the model was excluded from the model fit because 
the baseline sclerostin level was more than ten-folds higher than the other dose 
arms and that the dose-response changes were not consistent with the other 
dose arms.  Excluding this 750mg IV Q2W dosing arm resulted in a better fit 
in all other doses arms and the total sclerostin profile demonstrated a dose-
dependent relationship. Figure 14 illustrates the model prediction adequately 
described the observed sclerostin profiles.  
6.1.1. Romosozumab TMDD model 
Only mean romosozumab serum concentration profiles after single 
doses of SC and IV romosozumab
55
 and no sclerostin information was 
available in the literature. The mean PK profile demonstrated similar non-
linear clearance mechanism as blosozumab with distinct slopes in the terminal 
phase that varied with the drug concentration suggesting saturable kinetics. 
Furthermore, both blosozumab and romosozumab are IgG antibodies and 
therefore it was reasonable to assume that both molecules have similar model 
structure and PK characteristics. We elected to fix the sclerostin-related 
kinetics (𝑘𝑑𝑒𝑔and 𝑆𝑐𝑙0) to the parameter estimates obtained from blosozumab 
because of the lack of sclerostin information from romosozumab trials. This 
approach assumed that since the target and receptors are shared parameters 
that differ not by the drug therapies but by patient population; and both drugs 
are both indicated osteoporosis for the same patient population. Binding 
 83 
 
properties and drug distribution kinetics, however, varies with different drugs 
and 𝑉 , 𝑉2, 𝐶𝐿, 𝑄, 𝑘𝑎, 𝐹 , 𝑘𝑖𝑛𝑡 and 𝐾𝐷 , were estimated using phase 1 single 
dose romosozumab PK profiles
55
. 
Estimated bioavailability of the romosozumab after SC injection was 
about 70.7%. The central and peripheral volumes of distribution of 
romosozumab were estimated to be 2770 mL and 2870 mL, respectively, and 
the linear clearance and rate of absorption were 7.76 ml/h and 0.0129 h
-1
, 
respectively, and the estimated binding coefficient (𝐾𝐷) for romosozumab was 
0.216 pmol/ml (Table 7).  
 
Table 7 Pharmacokinetic/pharmacodynamics parameters for 





Volume of central compartment , 𝑉 (mL) 2520a 2770d 
Volume of peripheral compartment , 𝑉2 (mL) 1440a 2870d 
Linear clearance, 𝐶𝐿 (mL/h) 8.82a 7.76d 
Inter-compartmental clearance, 𝑄 (mL/h) 16.8a 33.1d 
Rate of absorption, 𝑘𝑎 (1/h) 0.00697a 0.0129d 
Bioavailability, 𝐹 
























Baseline sclerostin, 𝑆𝑐𝑙0 (pmol/ml)  0.259b,c 
a 
Fixed to values in Table 4       
b 




Assumed to be independent of drug and fixed for blosozumab and romosozumab.  
d 










Abbreviation: Q2W=once every 2 weeks, Q4W=once every 4 weeks; P1=phase 
1 trial; P2=phase 2 trial. i.v.=intravenous infusion; s.c.=subcutaneous 
injection. 
Note: 750mg i.v. Q2W was not included in the target-mediated drug disposition 
model. See discussion in section 6.1.1. 
Figure 14 Goodness of fit of (A) sclerostin concentration time profile 
and model predictions following blosozumab treatment 
and (B) romosozumab concentration time profile and 




6.2. Bone Biomarker Turnover Model 
With the knowledge of the kinetics profile of total and unbound 
sclerostin, we integrated the mechanism of sclerostin regulation, using the 
unbound sclerostin level as a driving force, into the bone remodeling model. 
Recently, the Metrum research group published a model with sclerostin 
regulation added to a multi-scale bone systems model
90
. Our attempt to add 
sclerostin effect on bone homeostasis was similar but was based on the 
minimal model
6
 instead of the expanded multi-scale model
102
. The minimal 
model retained only the most important characteristics of bone cells 
interaction and minimized the number of number of parameters that need to be 
estimated. 
Table 8 summarizes the parameter estimates associated with the bone 
remodeling model. Most of the parameters were from the original model
6
. The 
rate of osteoclast apoptosis (𝐷𝐴) was estimated by fitting the P1NP and CTX 
biomarkers as described in Section 5.2.2.8. The development of the biomarker 
responses were much slower compared with the profiles in the original model 
and the rate of elimination of AOBs (𝑘𝑏), differentiation rate of ROBs (𝐷𝑅), 
and maturation of ROBs (𝑑𝐵) were decreased by one order of magnitude from 
the original parameter estimates, to reflect the slower rate of cellular turnover. 
Table 9 summarized the parameter estimates of the sclerostin regulation of 
bone remodeling fitted with phase 1 and phase 2 blosozumab data. Figure 15 
and Figure 16 show predicted total and unbound sclerostin levels following 
blosozumab and romosozumab treatments. The unbound sclerostin was used 
as the input signal for the regulating the bone remodeling model as per 








Abbreviation: Q2W=once every 2 weeks, Q4W=once every 4 weeks; P1=phase 1 trial; 
P2=phase 2 trial. i.v.=intravenous infusion; s.c.=subcutaneous injection. 
Figure 15 Predicted percentage change from baseline of (A) total 
sclerostin and (B) unbound sclerostin concentration-time 
profile after singles and multiple doses of blosozumab 









Abbreviation: Q2W=once every 2 weeks, Q4W=once every 4 weeks; QM=once every 
month; Q3M=once every 4 months. i.v.=intravenous infusion; s.c.=subcutaneous 
injection; P1=phase 1 trial; P2=phase 2 trial. 
Figure 16 Predicted percentage change from baseline of (A) total 
sclerostin and (B) unbound concentration-time profiles 
after single and multiple doses of romosozumab treatment 






Table 8 Parameter Estimates for the Bone Remodeling Model 
Parameter Description Estimate 
a
 
𝐴𝑂𝐶𝑠𝑠 osteoclast numbers at steady state  9.13 x 10
-4
 pM 
𝐶𝑠  value of C to get half differentiation flux 0.005 pM 
𝐷𝐴  rate of osteoclast apoptosis caused by TGF-β 0.0533 1/h b 





𝐷𝑅  differentiation rate of osteoblast progenitors 2.92 x 10-6 pM/h b 
𝑓0 fixed proportion 0.05 (unitless) 
𝑅𝐴𝑁𝐾  fixed concentration of RANK 10 pM 
𝑘1 rate of OPG-RANKL binding 4.17 x 10
-4
 1/pM/h 
𝑘2  rate of OPG-RANKL unbinding 0.417 1/h 
𝑘3  rate of RANK-RANKL binding 2.42 x 10
-5
 1/pM/h 
𝑘4  rate of RANK-RANKL unbinding 7.08 x 10
-4
 1/h 
𝑘5  rate of PTH binding with its receptor 8.33 x 10
-4
 1/pM/h 
𝑘6  rate of PTH unbinding 0.125 1/h 
𝑘𝐵  rate of elimination of active osteoblast 7.88 x 10-4 1/h b 
𝐾𝑃𝐿 
maximum number of RANKL attached on 





𝑘𝑂  rate of elimination of OPG 0.0146 1/h 





𝑘𝑝  rate of elimination of PTH 3.58 1/h 
𝑃𝑇𝐻0 PTH concentration at steady state 50.4 pM/h 
Abbreviation: AOC=active osteoclast; TGF-β=transforming growth factor; 
OPG=osteoprotegerin; PTH=parathyroid hormone; RANK=Receptor activator of nuclear 
factor κ-B; RANKL=RANKL ligand. 
a




 Estimated / calibrated with the blosozumab biomarkers observations 
 
Table 9 Parameter Estimates for sclerostin effect on P1NP and 
CTX profiles using the bone remodeling model 
Parameter Description Estimate  
𝛽𝑂𝑅 





Concentration of sclerostin that cause half maximal 
inhibition of osteoblast maturation 
0.198 nM 
𝛽𝑂𝐵 





Concentration of sclerostin that cause half maximal 
stimulation of osteoblast apoptosis 
0.0153 nM 




Concentration of sclerostin that cause half maximal 
stimulation on RANKL 
0.0691 nM 




Concentration of sclerostin that cause half maximal 




Figure 17 shows the goodness-of-fit between the observed P1NP and 
CTX in the phase 1 and phase 2 blosozumab studies used to calibrate the 
model parameters. The model was able to describe the general trend of the 
bone formation and bone resorption. There was a rapid increase in the P1NP 
level following anti-sclerostin treatment. After repeated dosing, the maximum 
response began to decline despite serum sclerostin remaining neutralized and 
suppressed at a steady level (Figure 15). The model can reasonably describe 
this development of tolerance in the bone formation marker response. The 
CTX response was more varied. After anti-sclerostin treatment, there was an 
initial decline in the total CTX level, followed by a return to baseline and 
rebound beyond baseline during repeated dosing. There was a sharp rebound 
of the CTX levels beyond baseline after the treatments were discontinued. 
Although the model fit was not perfect, the model was able to describe the 
trend of the CTX levels to a reasonable extend whereby the initial CTX drop 
and the subsequent rebound toward baseline levels and beyond were consistent 
with the observations. Large variability associated with the CTX response 
were well documented
127
. Intrinsic biological variations play a part in CTX 
measurements variations. For example, daily and seasonal circadian cycle, 
effects of food intake as well as age and physical activities level can all affect. 
These factors affect bone resorption levels and CTX measurements can vary in 
the range of ± 30%
127
. Therefore, the goal of the model fit of CTX is not for 
the model to pass through all the observation points, which is not possible due 
to the inherent large biological variability in the CTX measurement, but rather 
to have the model describe the general trend of the CTX kinetics. The model 








Abbreviation: Q2W=once every 2 weeks, Q4W=once every 4 weeks; i.v.=intravenous 
infusion; s.c.=subcutaneous injection; P1=phase 1 trial; P2=phase 2 trial; 
CI=confidence interval. 
Figure 17 Goodness-of-fit of percent change from baseline of 
observed (A) P1NP and (B) CTX concentration-time 
profiles and model predictions after single and multiple 




6.3. Bone Mineral Density Model 
Table 10 summarizes the parameter estimates obtained from the BMD 
model fitted with the lumbar spine and total hip BMD responses from 
blosozumab trial
59
.  Figure 18 illustrates the goodness-of-fit of the BMD 
model overlaying the model predictions with the observed BMD that was used 
to estimate the model parameters. Generally, the goodness-of-fit of the model 
demonstrated that the model could adequately describe the observed data. 
 
Table 10 Parameter Estimates of the Lumbar Spine and Total Hip 
BMD Model 
Parameter Description Estimate  
Lumbar spine 
𝑘𝑖𝑛𝐿𝑆𝐵𝑀𝐷 Rate of lumbar spine BMD production 0.0769 1/week 












𝑘𝑖𝑛𝐻𝐼𝑃𝐵𝑀𝐷 Rate of Total Hip BMD production 0.0714 1/week 

































Abbreviation: Q2W=once every 2 weeks, Q4W=once every 4 weeks; CI=confidence 
interval. 
Figure 18 Goodness-of-fit of (A) lumbar spine and (B) total hip BMD 
overlay with observed data following single and multiple 




6.4. Model Qualification 
6.4.1. Romosozumab TMDD Model  
For model validation, the romosozumab PK model was used to predict 
the exposures after multiple doses of romosozumab and compare with the 
reported values of drug exposure as reported in multiples dose romosozumab 
study (Table 11)
56
. 1000 Monte-Carlo simulations per dosing arm were 
simulated with 15% (coefficient of variation, CV%) inter-individual 
variability added to the PK parameters. The non-compartmental analysis 
parameters were computed and summarized from the simulations and reported 
in Table 11.  The model was able to predict the drug exposure within the 
reported confidence limits
56
. The TMDD model for romosozumab was 
adequate and can predict the PK profiles reasonably well, despite only limited 






 Table 11 Comparison of observed and model predicted romosozumab exposure 
Mean ± SD 






1mg/kg 2mg/kg 2mg/kg 3mg/kg 1mg/kg 2mg/kg 2mg/kg 3mg/kg 
 
Q2W Q4W Q2W Q4W Q2W Q4W Q2W Q4W 
Parameter (n=5) (n=6) (n=5-6) (n=5)         
At first dose 
    
        
   tmax (day)
 c
 3 (2-5) 3 (3-5) 4.5 (3-7) 3 (3-5) 4 (2-6) 4 (2-6) 4 (2-6) 4 (2-6) 
   Cmax (μg/mL) 6.80 ± 1.86 15.7 ± 4.6 14.8 ± 6.0 24.5 ± 6.8 5.32 ± 1.19 12.1 ± 2.38 12.1 ± 2.39 19.1 ± 3.48 
   AUCτ (μg*day/mL)
d
 65.5 ± 15.6 202 ± 48 152 ± 63 340 ± 73 50.8 ± 12.4 170 ± 43.4 126 ± 25.3 298 ± 65.7 
At last dose 
    
    
   tmax (day)
 c
 3 (0-5) 3 (1-4) 3.5 (3-5) 5 (2-7) 3 (2-4) 4 (2-6) 4 (2-4) 4 (2-6) 
   Cmax (μg/mL) 14.2 ± 4.3 16.7 ± 3.3 27.8 ± 8.4 29.5 ± 8.7 9.30 ± 2.83 14.0 ± 3.25 26.0 ± 6.2 23.7 ± 5.26 
   AUCτ (μg*day/mL)
 d
 141 ± 41 231 ± 58 321 ± 97 462 ± 97 97.9 ± 35.7 207 ± 68.0 301 ± 80.6 393 ± 118 
   t1/2 (day) 7.02 ± 3.52 6.51± 1.37 9.32 ± 1.88 6.84 ± 1.79 5.50 ± 1.85 4.97 ± 1.23 8.72 ± 3.73 5.28 ± 1.84 
   AUC ratio, last/first 2.15 ± 0.45 1.17 ± 0.26 2.35 ± 0.90 1.35 ± 0.19 1.88 ± 0.33 1.2 ± 0.11 2.37 ± 0.35 1.3 ± 0.14 
Abbreviation: AUC=area under the concentration-time curve; AUCτ=AUC during one dosing interval; Cmax=maximum observed concentration; 
tmax=time of Cmax; t1/2=terminal half-life; Q2W=once every 2 weeks, Q4W = once every 4 weeks; SD= standard deviation 
a




 1000 Monte-Carlo simulations. 
c
 Median (minimum – maximum) 
d
 AUCτ range was 0-14 days for Q2W dose cohort and 0-28 days for Q4W dose cohort 
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6.4.2. Bone biomarker and BMD prediction  
For model qualification, the model was used to predict the P1NP and 
CTX responses following romosozumab administration (Figure 19). The 
simulated P1NP profiles were consistent with the observed data from the 
phase 1 and phase 2 romosozumab trials. In particular, the model was able to 
predict the P1NP response in the longer frequency regimens (Q3M), despite 
the Q3M regimen was not in the blosozumab model calibration dataset. The 
model could reliably predict the magnitude of the P1NP increase initially and 
the decline in the response during treatment subsequently. The model was also 
able to predict the drop in the P1NP level below the pretreatment baseline 
level early in the treatment period. The mean model predictions were within 
the standard error or the 95% confidence interval of the observed data. The 
CTX response following romosozumab treatment, however, was less well 
predicted (Figure 19). In the phase 1 single-dose romosozumab CTX response, 
the model predicted sharp rebound after the initial decrease in the CTX levels. 
The treatment regimens in multiple-dose romosozumab trials employed longer 
interval dosing frequency (Q4W, QM and Q3M) and the model predicted large 
fluctuations in the CTX levels occurring in the intervals between dosing 
events. Nonetheless, the model predictions passed through most of the 
observation data points and could account for the initial CTX level decrease 
following anti-sclerostin therapy. Figure 20 shows the model prediction of the 
lumbar spine and total hip BMD predictions against the observations 
following romosozumab treatments. The model predictions of BMD changes 








Abbreviation: Q2W=once every 2 weeks, Q4W=once every 4 weeks; i.v.=intravenous 
infusion; s.c.=subcutaneous injection; QM=once every month; Q3M=once every 3 
months; CI=confidence interval; SE=standard error. 
Figure 19 Prediction of (A) P1NP and (B) CTX concentration time 
profile against observed data after single and multiple 








Abbreviation: Q2W=once every 2 weeks, Q4W=once every 4 weeks; i.v.=intravenous 
infusion; s.c.=subcutaneous injection; QM=once every month; Q3M=once every 3 
months; CI=confidence interval. 
Figure 20 Prediction of (A) lumbar spine and (B) total hip BMD 
overlay with observed percent change from baseline (± 
95% CI) following single  and multiple doses of 




6.4.3. Defining the Boundary of Model Simulation 
We simulated the scenario when sclerostin was fully inhibited and 
predicted what the maximum increase in lumbar spine BMD will be. This 
defines the upper limit of lumbar spine BMD increase and physiologically this 
corresponds to sclerosteosis or van Buchem disease. 
Sclerosteosis and van Buchem disease are two diseases that cause high 
bone mass in sufferers. The diseases are very rare and are limited mainly to a 
small European population in South Africa and Netherlands
111,128
. There are 
less than 30 literature reported cases of van Buchem disease
129
 and about 60 
reported cases of sclerosteosis
130
. Sclerosteosis and van Buchem disease are 
both autosomal recessive disorders that display impressive increases in 
BMD
131
. Sclerosteosis patients are characterized by facial bone deformation, 
tall stature and syndactyly (fused fingers).  Van Buchem disease, on the other 
hand, is a more benign condition whereby the patients display less prominent 
bone enlargement symptoms. Both sclerosteosis and van Buchem disease are 
caused by a defective SOST gene that produces non-function sclerostin
132
.  
Mutation in a regulatory region downstream of the SOST gene was found in all 
van Buchem disease patients, suggesting that the condition can be caused by a 
loss-of-function gene or an impairment of the gene expression regulation. Low 
levels of sclerostin can be measured in van Buchem disease patients whereas 
no detectable level of sclerostin is found in sclerosteosis patients
111,128
, linking 
the level of serum sclerostin to the disease severity. 
  The lumbar spine BMD response was simulated by setting sclerostin 
production (𝑘𝑠𝑦𝑛) parameter to zero to replicate when sclerostin is completely 
eliminated. The model-predicted BMD response was then compared with the 
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estimated BMD (based on reported z-scores) of van Buchem disease and 
sclerosteosis patients compared with the reference population. BMD is higher 
in both van Buchem disease and sclerosteosis patients compared with the 
reference population
128,131,133
. The BMD in van Buchem disease and 
sclerosteosis patients were more than 50%-150% compared with healthy age-
matched subjects (Figure 21). There was a wide range of BMD measurements 
reflecting the wide extent of disease severity as well as a large age interval in 
the data from a limited patient population of these rare diseases. Our model 
predicted that the lumbar spine BMD response in complete sclerostin 
shutdown after anti-sclerostin therapy was 142% of the pre-treatment baseline 
(Figure 21). Our model suitably predicted BMD responses in the small patient 
population with sclerostin deficiency and reasonably defined a maximum 





Note: BMDs were estimated from the z-scores extracted from the references. The 
reference population for the van Buchem disease patients and carriers were 
Caucasian males stratified by age; and the reference population for the 
sclerosteosis patients and carriers were Caucasian stratified by gender and age 
from the NHANES III database. 
Abbreviations: NHANES=National Health and Nutrition Examination Survey 
a








 Lierop et al., 2013
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Figure 21 Estimated BMD differences compared to reference 
population in Van Buchem disease and sclerosteosis and 






7. Simulation Experiments and Applications of the 
Models 
The final models from the population PK-PD analysis and the extended 
bone remodeling systems pharmacology analysis were used to carry out 
simulation experiments to translate the model parameters and mathematical 
equations into useful visualizations and meaningful metrics that can be better 
interpreted and applied to improve trial design and dosing strategies for anti-
sclerostin therapies. Note that all the simulations experiments were performed 
using the subcutaneous administration of blosozumab as this is the intended 
route for the anti-sclerostin antibody therapies.  The population PK-PD model 
was used to perform Monte Carlo simulations, by incorporating the inter-
individual and residual variability, to assess the impact of dosing interval and 
body weight within the clinically relevant dose ranges and reasonable clinical 
observation periods (Section 7.1). Correspondingly, the extended bone 
remodeling bone was used to performed summary level simulations (i.e., no 
variability on the parameter estimates) to evaluate the effects of longer 
durations, wider dose ranges and dose intervals on the drug exposures, 
biomarker and BMD responses (Section 7.2). The differences, advantages and 
limitations of the population PK-PD model and the extended bone remodeling 
model were then compared and recommendations for how to use the different 
models to answer different questions were discussed in Section 7.3. 
7.1. Population PK-PD Model Simulations 
The population PK-PD model was used to refine and investigate the 
impact of the body weight on the drug exposure and BMD efficacy of 
different clinically meaningful dose regimens predicted by the extended bone 
remodeling model (Section 7.2). 200 trials each with 200 non-Japanese virtual 
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subjects with body weights of 30, 50, 70, 90 and 110kg (total 1000 subjects 
per trial) were simulated to predict the blosozumab exposure and BMD 
responses following 1 year of 135mg Q1W , 270mg Q2W, 540mg Q1M, 
1620mg Q3M, 3240mg Q6M, 540mg Q3M and 540mg Q6M blosozumab 
administered subcutaneously.  
7.1.1. Effect of Dosing Interval on Drug Exposure and BMD Responses 
Figure 22 (A) illustrates the predicted median and 90% prediction 
interval of blosozumab steady state PK profiles of the different dose regimens. 
Based on the theoretical dissociation coefficient (KD, 21.4 nM [Table 6]), the 
estimated drug concentrations that would achieve 50%, 80% and 90% target 
engagement were 21.4 nM, 85.6 nM and 192 nM, respectively. The trial 
simulations showed that 135mg Q1W, 270mg Q2W and 540mg Q1M 
regimens were able to attain above 50% target engagement at steady-state 
exposures. Additionally, 135mg Q1W and 270mg Q2W regimens could 
consistently attain above 80% target engagement even at the lower end of the 
prediction interval. On the other hand, the regimens with longer treatment 
dosing intervals (1620mg Q3M, 3240mg Q6M, 540mg Q3M and 540mg 
Q6M) had periods where the exposure fell below 50% target engagement. 
There is also greater difference between the maximum and minimum 
concentrations. The average concentrations at steady state (Cav,ss) were also 
most similar between the 135mg Q1W, 270mg Q2W and 540mg Q1M 
regimens and they have the most stable concentration profiles (i.e., lower 
peak-to-through concentration ratio) (Table 12 and Figure 22).  
Figure 22 (B) and (C) show the predicted lumbar spine and total hip 
BMD response following various dosing regimen. Q1W, Q2W and Q1M 
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regimens were the most similar and gave similar BMD responses. The 
predicted lumbar spine BMD increase at one year for 135mg Q1W, 270mg 
Q2W and 540mg Q1M were 17.2% (95% CI: 15.0, 20.3), 17.3% (95% CI: 
15.2, 20.5) and 17.2% (95% CI: 15.2, 20.0), respectively; and the predicted 
total hip BMD increase at one year for 135mg Q1W, 270mg Q2W and 540mg 
Q1M were 5.65% (95% CI: 4.34, 7.22), 5.72% (95% CI: 4.44, 7.26), 5.67% 
(95% CI: 4.48, 7.15), respectively (Table 13).  These regimens are considered 
similar, in terms of efficacy, and can be considered for further investigations.  
Two regimens with longer dosing interval 540mg Q3M and 540mg 
Q6M were also simulated. The predicted lumbar spine BMD increase at one 
year for 540mg Q3M and 540mg Q6M were 10.4% (95% CI: 8.03, 12.4) and 
5.27% (95% CI: 3.31, 6.95); and the predicted total hip BMD increase at one 
year for were  3.27% (95% CI: 2.22, 4.37), 1.54% (95% CI: 0.77, 2.32) 
respectively (Table 13). The longer dosing interval regimens were predicted to 
have a lower BMD response, suggesting that more frequent dosing is required 
to maintain efficacy despite tolerance development in the bone formation 
marker response.  
The simulation predicted that the 135mg Q1W regimen would produce 
the most consistent drug exposure and provide the best target neutralization 
profile throughout the treatment duration. The 540mg Q1M regimen, however, 
can also be considered based on the similar efficacy response with the 135mg 
Q1W and 270mg Q2W regimens. Weekly or monthly dosing frequency could 
potentially be a more attractive dose regimen to implement, compared to once 
every 2 weeks, as it may be easier for patients to remember. A monthly dose 
regimen can further ease the inconvenience and discomfort as the number of 
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subcutaneous injections patients will have to administer is reduced; potentially 





















Abbreviation:  Q1W= once every week; Q2W= once every two weeks; Q1M= once 
every month; Q3M= once every two months; Q6M= once every 
six months; TE=target engagement. 
 
With the final population PK model, simulations with 1-year treatment of blosozumab 
administered subcutaneously were conducted in 1000 virtual patients to achieve steady 
state.  The medians and 90% prediction intervals were presented. Horizontal lines 
were blosozumab concentrations associated with 50%, 80%, or 90% target 
engagement (based on the dissociation coefficient (KD= 21.4nM). 
 
Figure 22 Simulated median (90% PI) (A) blosozumab serum 
concentration at steady state and (B) lumbar spine and (C) 
total hip BMD response as percent change from baseline 
(%CFB) following various regimens of 1-year 






Table 12  Comparison of simulated average steady state 
blosozumab exposure following subcutaneous 
administration of various dose and dosing interval of 
blosozumab for 1 year 
Median (90% Prediction Interval) 
  AUCτ,ss Cav,ss 
Regimen (pmol·hr/mL) (nM) 
135mg Q1W 42000 (17800,80300) 250 (106,478) 
270mg Q2W 83200 (34500,164000) 248 (103,489) 
540mg Q1M 158000 (76100,313000) 217 (104,430) 
540mg Q3M 130000 (68500,255000) 59.7 (31.4,117) 
540mg Q6M 133000 (68500,257000) 30.5 (15.7,58.9) 
 
Abbreviation:  AUC=area under the concentration time curve; AUC(0-168)=AUC from zero 
to 168 hours; AUCτ,ss=AUC during one dosing interval at steady state; Cav,,ss=average 
concentration at steady state;   Q1W= once every week; Q2W= once every two weeks; 
Q1M= once every month; Q3M= once every two months; Q6M= once every six months. 
 
Table 13  Summary of population PK-PD model predicted median 
BMD change from baseline following 1 year of 
blosozumab treatment administered subcutaneously 




Lumbar Spine  Total Hip 














































Abbreviation:  Q1W= once every week; Q2W= once every two weeks; Q1M= once every 
month; Q3M= once every two months; Q6M= once every six months. 
a
 Summarized from 200 virtual clinical trials which were simulated to predict lumbar 





7.1.2. Effect of Body Weight on Drug Exposure and BMD Responses 
Body weight was identified as a covariate on the clearance and 
volumes of distribution of blosozumab and so body weight differences could 
lead to different drug exposure profiles and possibly BMD responses. Model 
simulation was performed to evaluate if dose adjustments by body weight was 
necessary. 
Simulations were generated to evaluate the drug exposure at steady 
state and BMD responses for patients with different body weights (30, 50, 70, 
90, and 110kg).  For each combination of body weight and dose regimen, 
simulations were conducted in 200 virtual patients with the final PK and BMD 
models. Simulations showed that the exposure difference between the patients 
weighing 30kg and 110kg were approximately two-fold in the five different 
treatment regimens explored (135mg Q1W, 270mg Q2W, 540mg Q1M, 
540mg Q3M, 540mg Q6M) (Table 14). Figure 23 illustrates the steady-state 
blosozumab concentration profiles for various dose regimens stratified by 
body weight. According to this simulation, in the 135mg Q1W, 270mg Q2W 
and 540mg Q1M regimens, patients across the wide range of body weight will 
have at least 50% of target neutralization throughout the treatment duration 
(Figure 23).  For the regimens with shorter dosing intervals (135mg Q1W and 
270mg Q2W), patients across all body weight will have at least 80% of target 
neutralization throughout the treatment duration (Figure 23). Therefore, 135mg 
Q1W, 270mg Q2W and 540mg Q1M regimens, were expected to consistently 
maintain target engagement across different body weights and dose 
adjustments were not necessary. Fixed-dose blosozumab was predicted to 
perform well across body weight in regimens with smaller dosing intervals. 
Consequently, the predicted differences of BMD responses in both lumbar 
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spine and total hip are the smallest across 30- to 110-kg body weight in 
regimens with the smaller dosing intervals (135mg Q1W, 270mg Q2W and 
540mg Q1M regimens) (Figure 23). 
 
Table 14 Comparison of simulated steady state blosuzumab 
exposure stratified by body weight following 1 year 
treatment of blosozumab administered subcutaneously. 





























































 Simulated and summarized with the final population PK model in 1000 virtual patients. 
Since body weight was identified to be covariate for saturable clearance and central volume, 













Abbreviation:  Q1W= once every week; Q2W= once every two weeks; Q1M= once 
every month; Q3M= once every two months; Q6M= once every 
six months; TE=target engagement. 
With the final population PK model, for each combination of body weight and dose 
regimen, simulations with 1-year treatment of blosozumab administered 
subcutaneously were conducted in 1000 virtual patients to achieve steady state.  The 
medians were presented. Horizontal lines were blosozumab concentrations associated 
with 50%, 80%, or 90% target engagement (based on the dissociation coefficient (KD= 
21.4nM). 
 
Figure 23 Simulated median (90% PI) (A) blosozumab serum 
concentration at steady state and (B) lumbar spine and (C) 
total hip BMD response as percent change from baseline 
(%CFB) following various regimens of 1-year treatment of 
blosozumab administered subcutaneously and 1-year 





7.2. Extended Bone Remodeling Model Simulations 
 We simulated the different blosozumab dosing regimens to investigate 
how the bone biomarker responses relate to BMD changes. By altering the 
doses and dosing frequencies, how will the drug exposure change and how 
will BMD responses be affected? Based on the observed P1NP responses that 
showed attenuated responses after repeated dosing
56–58,107
; will a longer dosing 
interval improve the recovery of the bone formation by allowing time for the 
ROB pool to build up and mitigate the attenuation of P1NP response during 
treatment period?  To answer these questions, we simulated 135mg Q1W, 
270mg Q2W, 540mg Q1M of blosozumab administered subcutaneously which 
were predicted to give similar drug exposure. The doses considered were 
practical, meaning it can potentially be manufactured into a viable medical 
product with suitable delivery device, and were within range of the doses 
tested clinically and did not show any safety concerns (the largest dose studied 
clinically was 1100mg IV single dose blosozumab in study 2) . 540mg Q3M 
and 540mg Q6M were also investigate to evaluate how a longer dosing 
interval at a fixed-dose affected the biomarker and BMD responses. Figure 24 
shows the predicted drug exposure, biomarker and BMD responses following 
one-year treatment of 135mg Q1W, 270mg Q2W, 540mg Q1M, 540mg Q3M 




7.2.1. Effect of Dosing Interval on Drug Exposure and BMD Responses 
135mg Q1W, 270mg Q2W and 540mg Q1M performed similarly in 
terms of BMD responses. Predicted lumbar spine change from baseline were 
25.9%, 26.1% and 23.3% while total hip BMD change from baseline were 
7.72%, 7.81% and 7.11% at one year after 135mg Q1W, 270mg Q2W and 
540mg Q1M respectively (Table 15). Figure 24 (C) shows that 540mg Q3M 
and 540mg Q6M dose regimen did not allay the attenuation in the P1NP 
response in subsequent doses, refuting the hypothesis that a longer dosing 
interval will counter the development of tolerance in the P1NP response, at 
least in the dosing regimens investigated in the simulation. P1NP response 
after the first 540mg dose increased more than 150% followed by a decrease 
towards pretreatment baseline with a small overshoot during the first dosing 
interval. Repeat doses failed to achieve the same level of P1NP response and 
the responses were lower in magnitude compared with the first dose. Another 
observation was that repeated dosing alters the steady-state magnitude of the 
P1NP responses. The initial maximum magnitude of P1NP responses after 
135mg Q1W, 270mg Q2W and 540mg Q1M were 148%, 153% and 176%, 
respectively. The maximum response declined thereafter and reached a steady 
level by about 9 months and the maximum P1NP responses were 34.3%, 
34.0% and 28.7%, respectively, at steady state. The 540mg Q3M and 540mg 
Q6M regimens, because of the greater intervals between doses, had greater 
fluctuations in the P1NP responses. Between each dosing intervals there were 
extended periods where the P1NP responses were below the pretreatment 
baseline levels. At each dosing event, the P1NP responses increased and 
quickly dissipated, producing sharp spikes in the P1NP profiles, but the 
general P1NP profile remained largely below the pretreatment baseline levels. 
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Similarly, the maximum P1NP responses at repeated doses attained a steady 
state level by about 12 months of continuous treatment. The maximum P1NP 
responses after initial dose declined from 176% to 88.1% and 133%, following 
540mg Q3M and 540mg Q6M doses, respectively. This is an interesting 
observation and suggests that the longer dosing interval can retain a much 
higher maximum P1NP response in repeat doses. However, more frequent 
dosing can maintain better bone formation activities and keep the P1NP 
responses largely above the pretreatment baseline level. It also suggests that 
the systems need an even longer interval (more than 6 months) of recovery for 
the P1NP response to return to its pretreatment level. Nevertheless, the anti-
sclerostin therapy can drive bone formation activities in all the dosing 
regimens investigated here and initiate BMD accretion. 
Figure 24 (E) shows that the lumbar spine BMD change from baseline 
response dropped from 18.3% (540mg Q1M) to 8.63% and 4.91% for 540mg 
Q3M and 540mg Q6M, respectively (Table 15). Similarly, Figure 24 (F) 
shows that the total hip BMD change from baseline response dropped from 
5.97% (540mg Q1M) to 2.88% and 1.56% for 540mg Q3M and 540mg Q6M, 
respectively (Table 15). The model predictions suggest that more frequent 
dosing is required for the maintenance of the BMD response despite 
observation of tolerance response in the bone formation marker. It is attractive 
and scientifically logical to employ a longer dosing interval to counter the 
attenuation of the bone formation response by allowing time for new 
osteoblast recruitment and maturation. However, based on systematic analysis 
of the model, a more frequent dosing regimen is predicted to be more 





Table 15  Summary of bone remodeling model predicted mean BMD 
change from baseline following 1 year of blosozumab 
treatment administered subcutaneously 
 
Lumbar Spine Total Hip 
 
Year 1 Year 2 Year 1 Year 2 
135mg Q1W 19.4 6.58 6.28 3.72 
270mg Q2W 19.5 6.73 6.33 3.80 
540mg Q1M 18.3 6.19 5.97 3.49 
540mg Q3M 8.63 2.75 2.88 1.49 
540mg Q6M 4.91 2.03 1.56 1.09 
Abbreviation:  Q1W= once every week; Q2W= once every two weeks; Q1M= once every 



















Abbreviation:  BMD: bone mineral density CTX=serum type 1 C-terminal procollagen; 
P1NP=serum type-1 procollagen N-terminal; Q1W= once every week; Q2W= once every 
two weeks; Q1M= once every month; Q3M= once every two months; Q6M= once every 
six months; %CFB=percent change from pretreatment baseline. 
Figure 24 Prediction of (A) blosozumab concentration and (B) 
unbound sclerostin (C) P1NP, (D) CTX, (E) lumbar spine 
BMD and (F) total hip BMD following various dose 




7.2.2. Duration of Precursor Osteoblast Suppression and 
Replenishment 
The Q6M dosing regimen predicted that the P1NP levels did not return 
to baseline between doses (Figure 24 (C)); thereby suggesting that a longer 
interval, more than six months, between doses would be required for the 
preosteoblast pool to be replenished and P1NP level to return to pretreatment 
levels. Simulation of 540mg Q1M, Q3M, Q6M, Q9M (once every nine 
months), Q12M (once every year) and Q18M (once every one-and-a-half year) 
was performed to estimate the duration needed for the ROB to be replenished 
and P1NP levels to return to pretreatment levels.  Figure 25 (A) showed that 
the P1NP levels will take more than 18 months to return to baseline following 
one dose of anti-sclerostin antibody treatment. The simulated preosteoblast 
number decreased as anti-sclerostin therapy was administered. The precursor 
pool then slowly replenished itself taking more than 18 months to return to 
baseline level (Figure 25 (B)). The decrease in the precursor pool was about 
28.0% after the first dose. Shorter dosing interval regimens continue to deplete 
the precursor pool before the system was able to recover. With the repeated 
dosing, precursor pool continued to decrease and reached steady state level by 
about 12 months. The precursor pool decreased to about -69.5% in the 540mg 
Q1M regimen. Regimens with intervals longer than one month showed more 
fluctuations and the steady-state precursor pools fluctuated between -51.8% 
and -39.0% for 540mg Q3M, -40.0% and -19.9% for 540mg Q6M, -34.8% and 
-11.6% for 540mg Q9M, -32.1% and -7.00% for 540mg Q12M, and -14.5% 










Abbreviation:  CTX=serum type 1 C-terminal procollagen; P1NP=serum type-1 
procollagen N-terminal; Q1M= once every month; Q3M= once every two 
months; Q6M= once every six months. Q9M= once every nine months; 
Q12M= once every twelve months; Q18M= once every eighteen months; 
ROB=responding osteoblast; %CFB=percent change from pretreatment 
baseline. 
 
Figure 25 Prediction of (A) P1NP and (B) ROB following various 
dose regimens blosozumab treatment administered 
subcutaneously for 36 months 
 
 
7.2.3. Long-Term Anti-Sclerostin Treatment 
The extended bone remodeling model predicted that P1NP response 
achieved a steady level following about 12 months of repeated dosing; we 
simulated a longer term treatment to investigate when the BMD responses 
would attain steady state.  Figure 26 shows the lumbar spine and total hip BMD 
responses following 30 years of treatment followed by a 20-year observation 
period. The model predicted that both lumbar spine and total hip BMD 
responses would reach a plateau by about 5 and 15 years of 130mg Q1W 
continuous treatment, respectively; treatment thereafter would maintain the 
BMD responses at a steady-state. The predicted steady state lumbar spine 
BMD responses were 21.9%, 21.8%, 19.0%, 6.95% and 4.22% and the steady 
state total hip BMD responses were 13.6%, 13.5%, 11.4%, 3.55% and 2.21% 
following 135mg Q1W, 270mg Q2W, 540mg Q1M, 540mg Q3M and 540mg 
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Q6M, respectively. The model also predicted that when sclerostin inhibition is 
removed after treatment discontinued, the duration needed for lumbar spine 
and total hip BMD to return to pretreatment baseline level after 135 mg  Q1W 
discontinued were about 5 and 15 years. The duration to achieve steady state 
following treatment administration and return to baseline after treatment 
discontinued was affected by the treatment frequency. The turnover of lumbar 
spine and total hip BMD were different and unexpected BMD responses were 
predicted with different doses and dose frequencies (Figure 26).    
Lumbar spine BMD had a higher turnover rate and achieved a higher 
response  compared to total hip BMD and where steady state achieved post-
treatment and the return to baseline post-treatment discontinuation were faster 
(Figure 26). Interestingly, the model also predicted that the less frequent dosing 
regimens (Q1M, Q3M and Q6M) produced “overshoot” in lumbar spine BMD 
response in the first 2 years which then decreased to the steady state by the 
fifth year. After treatment discontinued, the BMD response returned towards 
pretreatment baseline in about 2 years. For the less frequent dosing regimens 
(Q1M, Q3M and Q6M), the BMD response demonstrated a rebound that 
caused the BMD to dip below and subsequently return to pretreatment 
baseline (Figure 26 (A)). Total hip BMD, on the other hand, did not predict 
overshoot or rebound profiles following anti-sclerostin treatment. The 
different long-term BMD profiles at different skeletal sites, an unexpected 
model prediction, reflected the reality that different skeletal sites grow and 
respond to anti-sclerostin therapy differently. Correspondingly, observations 
of the rare sclerosteosis and van Buchem disease patients revealed that bone 
thickening, due to loss of sclerostin, is different at different skeletal sites. For 
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example, the skull of a van Buchem disease patient can weigh nearly four 
times that of normal skull
122




The model predictions can have an impact on the design of clinical 
trials. The rate of bone turnover and the time to reach steady state for BMD 
increase in vertebral and non-vertebral skeleton are different as suggested by 
the model predictions; and therefore the fracture rates can also have temporal 
differences. For phase 3 clinical trials where fracture rate reductions are 
important clinical endpoints, vertebral and non-vertebral fracture rates may 
need different observation periods where the non-vertebral skeletal fracture 
might require a longer treatment and observation duration to attain 
differentiation with active comparator.   
It should be noted that long-term observations of BMD responses after 
anti-sclerostin treatment are lacking, unsurprising since the anti-sclerostin 
treatment is a new therapy under clinical development, and these predictions 
will need to be validated when more information becomes available. Also note 
that the model did not account for the general bone loss associated with age 
and hormonal change due to menopause. Therefore, the actual BMD response 
may be lower and the return to pretreatment baseline level could be more 
rapid. Nonetheless, the model is useful to inform the general trend of BMD 
responses following long term usage and give an indication when steady state 
will be achieved, as well as the time required for treatment effect to be washed 









Abbreviation:  BMD: bone mineral density; Q1W= once every week; Q2W= once 
every two weeks; Q1M= once every month; Q3M= once every two months; 
Q6M= once every six months; %CFB=percent change from pretreatment 
baseline. 
 
Figure 26 Prediction of (A) Lumbar Spine BMD and (B)Total Hip BMD 
following various dose regimens of blosozumab treatment 
administered subcutaneously for 30 years followed by 20 
years observation 
 
7.2.4. Dose-Response Curve of BMD improvement 
In vivo measurements of the sclerostin and bone biomarkers suggested 
that the bone formation rate decreases with age and that different levels of 
sclerostin can have different effects on the phenotypic expressions
111
. P1NP 
levels are higher in younger subjects implying that bone formation processes 
are more active in the young and possibly more susceptible to sclerostin 
regulation. In addition, the different degrees of bone deformation in 
sclerosteosis patients (no measurable sclerostin) and van Buchem disease 
patients (a more benign condition of increased bone mass with reduced serum 
sclerostin level) imply that the sclerostin effect is not an all-or-none response; 
instead the levels can be controlled by varying levels of bone formation 
activity. Fine-tuning of the levels of target inhibition, therefore, can potentially 
be employed to titrate biomarker and BMD responses.  Our model provides 
the mathematical framework to measure changes in sclerostin levels and 
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quantitatively links it to the changes in the bone formation markers and BMD 
changes. This allows for precise calibration of dose and dosing frequencies 
which is crucial to optimize the benefits through computational modeling and 
simulations. 
Dose-response relation for lumbar spine and total hip BMD percent 
change from pre-treatment baseline were mapped out for different blosozumab 
doses and dosing intervals (Figure 27 and Figure 28). The BMD responses 
were higher with more frequent dosing and all dose regimens attained steady-
state levels by about 4 years of continuous treatment (Figure 27). The 
simulations suggested that a 2-year treatment instead of 1-year treatment 
might be a better observation duration for clinical investigation as the BMD 
responses continued to increase and can provide a better differentiation of the 
doses and against comparator. Simulations also suggest that the higher doses 
can be used to compensate for less frequent dosing. However, the doses will 
have to be increased more than dose-proportionally (i.e., two-fold increase in 
dosing interval demands a more than two-fold increase in dose amount to 
achieve the same drug exposure), due to the non-linear  pharmacokinetics 
characteristics.  For example, 135mg Q1W regimen attained a lumbar spine 
BMD increase of 19.4% after 1 year treatment. To attain the same lumbar 
spine BMD responses with less frequent dosing, 296mg Q2W, 594mg Q1M, 
2250mg Q3M and 4980mg Q6M regimens would be needed (Figure 28 (A)). 
Similarly 135mg Q1W regimen attained a total hip BMD increase of 6.28% 
after 1 year treatment. To attain the same total hip BMD responses with less 
frequent dosing, 267mg Q2W, 573mg Q1M, 1850mg Q3M and 3700mg Q6M 
regimens would be needed (Figure 28 (B)).  
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Generally, the clinical efficacious dose regimens (e.g., 135mg Q1W, 
270mg Q2W and 540mg Q1M) were at the steep slope of the curve and there 
was a potential to achieve higher BMD responses with higher doses (Figure 
28).  Given the non-linear PK and efficacy relationships, it is not possible to 
simply project efficacy responses for dose regimens that were not tested 
before. The model allowed us to explore different doses and to quantify the 















   
Abbreviation:  BMD=bone mineral density; Q1M= once every month; Q3M= once every 
two months; Q6M= once every six months. Q12M= once every twelve months; 
%CFB=percent change from pretreatment baseline. 
Figure 27 Temporal responses of (A) lumbar spine and (B) total hip 
BMD following various dose regimens of blosozumab 








   
Abbreviation:  BMD=bone mineral density; Q1M= once every month; Q3M= once every 
two months; Q6M= once every six months. Q12M= once every twelve months; 
%CFB=percent change from pretreatment baseline. 
 
Figure 28 Dose-Response relationship of (A) lumbar spine and (B) 
total hip BMD at 1 year following various dose regimens of 
blosozumab treatment administered subcutaneously. Left 






7.3. Comparison of Population PK-PD and Bone 
Remodeling Model 
George Box famously declared that, “Essentially, all models are 
wrong, but some are useful." 
135
. All models are simplifications of the reality 
and cannot possibly fully represent all the complexities in the underlying 
biological processes. However, these simple mathematical constructs can be 
useful and enable us to better understand the essential physiological pathways 
or answer critical questions that we have on hand. Two approaches, population 
PK-PD and systems pharmacology models, were employed to characterize the 
kinetics of anti-sclerostin therapy, bone turnover markers and BMD responses. 
In this section, we will compare the two models and discuss the strength and 
weaknesses of each model and demonstrate how these two models can be used 
to optimize dose regimens and investigate the impact of body weight on 
therapeutic outcomes. 
To compare the two models, a wide range of dose and dosing interval 
regimens were simulated to evaluate the drug exposure and therapeutic 
outcomes at clinically relevant dose ranges as well as at high dose to probe the 
limits of the system.  Blosozumab of doses 65mg, 95mg, 135mg, 270mg, 
540mg, 810mg, 1080mg, 1620 mg, 2160mg and 3240mg administered 
subcutaneously at intervals of Q1W, Q2W, Q1M, Q3M and Q6M for one year 
and observed for an additional year were simulated and the predicted drug 
exposures and clinical outcomes compared. Figure 29 shows the PK profiles 
predicted using the population PK-PD and systems biology TMDD model 
respectively. Based on visual inspection of the PK profiles, the exposures 
generated by either model at all doses and dosing intervals were similar and 
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therefore using either model to predict drug exposures will likely yield similar 
results and conclusions. 
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(A) Population PK Model (B) Target-Mediated Drug Disposition Model 
  
Abbreviation: Q1W= once every week; Q2W= once every two weeks; Q1M= once every month; Q3M= once every two months; Q6M= once every six 
months 
Note: (A) Simulations with 1-year treatment of blosozumab were conducted in 1000 virtual patients with the final PK model.  The medians and 90% 
prediction intervals (shaded area) were presented. (B) Simulations with 1-year treatment of blosozumab were conducted with the TMDD model.  Visual 
inspections of the profiles shows that drug exposure prediction using either model were similar. 
 
Figure 29 Predicted blosozumab serum concentration using (A) population PK model and (B) TMDD model at various 
blosozumab regimens administered subcutaneously for 1 year 
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Different BMD responses in high doses of blosozumab subcutaneous 
administration, however, were predicted by the population PK-PD model and the 
extended-bone remodeling model (Figure 30 and Figure 31). Figure 30 (A) and 
Figure 31 (A) showed that the maximum lumbar spine and total hip BMD 
responses, predicted by the population PK-PD model, reached their maximum of 
19.3% (95% CI: 17.1%, 24.3%) and 6.46% (95% CI: 5.31%, 8.44%) increase 
following 1 year of 3240mg Q1W blosozumab treatment, respectively. The 
extended bone remodeling model, on the other hand, predicted much higher BMD 
responses following high doses of the blosozumab treatment (Figure 30 (B) and 
Figure 31 (B)). The lumbar spine and total hip BMD, predicted by the extended 
bone remodeling model, achieved a maximum of 59.9% and 27.4% increase, 
respectively, following 1 year of 3240mg Q1W blosozumab treatment. The 
different BMD response predictions reflected the differences in the model 
assumptions and suggested that the two different models are useful to serve 
different purposes and answer different questions. Therefore, when making 
predictions using the different models, it is necessary to consider the models’ 
assumptions and understand the limitations and boundaries where the models are 





(A) Population PK-PD Model (B) Extended Bone Remodeling Model 
  
Abbreviation: BMD=bone mineral density; Q1W= once every week; Q2W= once every two weeks; Q1M= once every month; Q3M= once every two months; 
Q6M= once every six months; CI=confidence interval. 
Note: (A) Simulations with 1-year treatment of blosozumab were conducted in 1000 virtual patients with the final PK-PD model.  The medians and 90% 
prediction intervals (shaded area) were presented. (B) Simulations with 1-year treatment of blosozumab were conducted with the extended bone remodeling 
model. The population PK-PD model (A) predicted maximum median (95% CI) lumbar spine increase was 19.3% (17.1%, 24.3%) while the extended 
bone remodeling model predicted that the maximum lumbar spine BMD increase was 59.9% following 1 year of 3240mg Q1W blosozumab treatment. 
 
Figure 30 Predicted lumbar spine BMD percent change from baseline using (A) population PK-PD model and (B) 
extended bone remodeling model at various blosozumab regimens administered subcutaneously for 1 year 
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(A) Population PK-PD Model (B) Extended Bone Remodeling Model 
  
Abbreviation: BMD=bone mineral density; Q1W= once every week; Q2W= once every two weeks; Q1M= once every month; Q3M= once every two months; 
Q6M= once every six months; CI=confidence interval. 
Note: (A) Simulations with 1-year treatment of blosozumab were conducted in 1000 virtual patients with the final PK-PD model.  The medians and 90% 
prediction intervals (shaded area) were presented. (B) Simulations with 1-year treatment of blosozumab were conducted with the extended bone remodeling 
model. The population PK-PD model (A) predicted maximum median (95% CI) total hip BMD increase was 6.46% (5.31%, 8.44%) while the extended 
bone remodeling model predicted that the maximum total hip BMD increase was 27.4% following 1 year of 3240mg Q1W blosozumab treatment. 
 
Figure 31 Predicted total hip BMD percent change from baseline using (A) population PK-PD model and (B) extended 
bone remodeling model at various blosozumab regimens administered subcutaneously for 1 year 
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7.3.1. Discussions, Strengths and Limitations of Population PK-PD 
Model 
The population PK-PD model uses a pseudo-target engagement to link 
the drug exposure with the BMD responses (Section 3.2.4). The model 
parameter estimates were informed using the phase 2 blosozumab clinical 
trials and this limited the maximum response for lumbar spine and total hip 
BMD to 20.5% and 9.27% increase from pretreatment baseline (Table 6). The 
model performed well, stable and reliable, within the boundaries of the drug 
exposures that were investigated in the phase 2 blosozumab trials (Section 
4.5). The model can reasonably be used to predict dose regimens that were not 
studied before, but within the boundaries of drug exposure equivalent to 
270mg Q2W. 270mg Q2W was the dose regimen with the largest drug 
exposure studied, and this regimen sets the limits for the BMD responses.  
Qualifications of the PK-PD models were performed by inspecting the 
goodness-of-fit between the model predictions and observations, reviewing the 
residuals against the model predictions, and ensuring the fidelity of the models 
and observations was conserved through visual predictive checks. These were 
considered internal validation checks to ascertain the reliability and stability of 
the models, since the observations used for the checks were also used in the 
model building. External validation is encouraged but not necessary as per the 
FDA guidelines
136
. Our PK-PD models adequately described the data and 
quantified the variability. The models were deemed to reliably and stably 
reproduce clinical trial observations and robust enough to predict for future 
trials. 
Therefore, the population PK-PD model is useful for fine-tuning 
clinically relevant dose regimens and investigating dose and dosing 
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frequencies that are within the drug exposures tested clinically. In other words, 
the model simulation should only be used for interpolation of the dose 
regimens and trial designs. Extrapolation of the model beyond the drug 
exposure tested in the 2 blosozumab trial will need further examination and 
probably should not be used. The population PK-PD model is also useful for 
quantifying patient factors that affected the drug exposure and clinical 
outcomes. The nonlinear mixed-effect model utilized all patient-level data and 
quantified variability caused by patient factors as well as unidentified residual 
errors.  By mathematically quantifying the covariate effects, we can then 
investigate the impact that these covariate effects have on the system. We 
determined that body weight has an effect on the clearance and distribution of 
blosozumab (Sections 4.3) and will demonstrate that the impact of body 
weight differences on drug exposures and clinical efficacies may not be 
clinically meaningful in the dose ranges that were suitable for further clinical 
investigations in later section (Section 7.1.2). 
 
7.3.2. Discussions, Strengths and Limitations of the Extended Bone 
Remodeling Model 
The extended bone remodeling model linked drug exposure following 
anti-sclerostin treatment to unbound sclerostin levels which then affected the 
osteoblast and osteoclast interactions. The osteoblast and osteoclast numbers, 
reflected by the P1NP and CTX levels, then altered bone formation and 
destruction rates and drove the BMD responses (Section 5). The model 
successfully predicted the P1NP levels and adequately described the change in 
CTX levels following anti-sclerostin treatment. The BMD predictions were 
consistent with the observations after anti-sclerostin treatment and the model 
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also satisfactorily defined an upper boundary of BMD increase that mimics the 
disease condition of sclerosteosis and van Buchem disease when there is a 
complete shutdown of sclerostin regulation (Section 6.4.3). This allows for the 
model to be used to investigate dose regimens beyond the drug exposures that 
were tested clinically and with confidence that the sclerostin regulation in the 
model was within clinically observable limits. 
The extended bone remodeling model is useful to test a wide range of 
dose regimens including dose ranges that predict drug exposures beyond drug 
regimens that have been investigated clinically. For example, the extended 
bone remodeling model would be appropriate to investigate dose regimens that 
have drug exposures larger than 270mg Q2W 1-year blosozumab 
subcutaneous treatment, as simulations showed that the efficacy responses 
were not limited by the data used to inform the model parameters (Figure 30 
and Figure 31). Also, since the extended bone remodeling model included 
physiological processes based on in vitro and preclinical knowledge, the 
model is also useful to probe the systems components and generate hypotheses 
for the mechanism of action of sclerostin regulation of bone homeostasis.  
Figure 32 shows the predicted time profiles of various systems 
components in the extended bone remodeling model following increasing 
doses of Q1W subcutaneous blosozumab treatment. Figure 32 (A) shows that 
increasing the blosozumab dose increased the target neutralization of the 
unbound sclerostin. Even the smallest dose of 65mg Q1W neutralized the 
unbound sclerostin by more than 75% (Figure 32 (F)). Increasing the dose, 
thereafter, continued to improve the target neutralization, albeit marginally. 
This suggests the system is sensitive to small changes in the sclerostin level. 
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At the four intersection points of sclerostin regulation included in the extended 
bone remodeling model (𝜋𝑆𝑅 , 𝜋𝑆𝐵 , 𝜋𝑆𝐿 , and 𝜋𝑆𝑂 ), the active osteoblast 
apoptosis (𝜋𝑆𝐵 ) is the most affected by sclerostin levels with the greatest 
separation of the 𝜋𝑆𝐵 levels with different blosozumab doses (Figure 32 (B-E)). 
This implied that small changes in sclerostin level resulted in large responses 
in the 𝜋𝑆𝐵  levels and that a large portion of the anti-sclerostin treatment was 
possibly accomplished by inhibiting the apoptosis of active osteoblasts, thus 
improving their survival and bone formation activities. As the model is built 
based on biological processes, when new knowledge grows, the model can be 











 A  B  C  D  E 
 
 F  G  H  I  J 
 
 
Abbreviation:  AOB=active osteoblast; BMD=bone mineral density CTX=serum type 1 C-
terminal procollagen; P1NP=serum type-1 procollagen N-terminal; 𝜋𝑆𝑅=activator 
function of sclerostin regulation on ROB maturation; 𝜋𝑆𝐵=repressor function of sclerostin 
regulation on AOB apoptosis; 𝜋𝑆𝐿=repressor function of sclerostin regulation on RANKL: 
levels; 𝜋𝑆𝑂=activator function of sclerostin regulation on OPG levels; %CFB=percent 
change from baseline. 
Notes: (A) shows the increased target neutralization with increasing blosozumab doses. 
Although the lowest dose of 65mg Q1W achieved more than 75% target neutralization 
(F), the sclerostin regulations at  𝜋𝑆𝑅, 𝜋𝑆𝐵, 𝜋𝑆𝐿, and 𝜋𝑆𝑂 were not at their maximum 
levels (B-E). Increasing blosozumab dose improved the target neutralization marginally 
but resulted in greater sclerostin regulations (A-E). Osteoblast numbers (G), reflected by 
the P1NP %CFB, and osteoclast numbers (H), reflected by the CTX %CFB, continued to 
increase in their level of responses with increasing doses, even though the level of 
sclerostin changed marginally. Similarly lumbar spine (I) and total hip (J) BMD continues 
to increase with increasing doses. Simulation results suggested that the system was very 
sensitive to the sclerostin levels and small changes in the sclerostin levels can result in 
large changes in the bone cell interactions. Also, the survival of active osteoblast (𝜋𝑆𝐵) 
(C) was most affected by the changes in the sclerostin level and increased sclerostin 
neutralization with higher blosozumab doses greatly decreased the rate of osteoblast 
apoptosis. 
Figure 32 Predicted (A) sclerostin concentration, (B) 𝝅𝑺𝑹, (C) 𝝅𝑺𝑩, (D) 
𝝅𝑺𝑳, (E) 𝝅𝑺𝑶,  and (F) sclerostin, (G) P1NP, (H) CTX, (I) 
lumbar spine and (J) total hip BMD percent change from 
baseline following Q1W blosozumab  regimens of various 
doses administered subcutaneously for one year followed 




Nevertheless, there are limitations in using and interpreting the 
extended bone remodeling model. The extended bone remodeling model is a 
complex systems biology model with many parameters. As the individual 
components that formed the full model may not be practically measured in 
clinical trials, many of these parameter estimates were fixed to arbitrary 
constants or preclinical experimental values in an attempt to combine the 
different networks signals and cellular interactions into a coherent bone 
remodeling mathematical model. Despite the arbitrary assignment and fixing 
parameter estimates per the original Lemaire et al. model for some of model 
components, the model demonstrated predictive power by successfully 
replicated anti-sclerostin therapy trials and sclerostin knock-out disease state. 
The predictive capability of a systems biology model is a more important 
model evaluation criterion compared to identifying specific model 
subcomponents for complex systems biology models 
137
. 
There are improvements to be made to the model as we gain better 
understanding of the physiological mechanisms governing bone metabolism. 
The bone resorption (CTX) response predictions by the model were more 
irregular with model predictions fluctuating widely between dosing intervals. 
The model fitted and described satisfactorily the CTX responses following 
blosozumab treatment (Figure 17), but the prediction of the CTX responses 
following romosozumab were more irregular and less well defined (Figure 
19). Nonetheless, prediction lines pass through most of the observations. This 
implies that the sclerostin effect on bone resorption may not have been fully 
captured in the model and needs further improvement when more information 
becomes available. The difference in CTX response between blosozumab and 
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romosozumab could possibly be due to differences in laboratory processing 
and assay methods of the samples, different subject populations as well as 
different time and season of sample collection. CTX levels were known to 
fluctuate based on daily circadian rhythm, seasonal changes as well as the age 
and level of physical activities of the patient
127,138
. This is unsurprising given 
that CTX is a marker of bone resorption and bone metabolism is affected by 
these factors. Furthermore, magnitude of CTX changes after anti-sclerostin 
treatment were smaller than the variability in CTX measurement as evident 
from the both blosozumab and romosozumab observations (Figure 17 and 
Figure 19) and this variability posed a problem to accurately quantify the CTX 
profiles after antis-sclerostin treatment. Additionally, there are several 
methods of quantifying CTX levels. In phase 1 romosozumab trials, CTX was 
assayed using radioimmunoassay (RIA)
55
, while in the phase 2 romosozumab 
trials CTX was assayed using a commercial enzyme-linked immunosorbent 
assay (ELISA) kit
139
.  More differences yet, serum CTX from blosozumab 
trials were analyzed using a different commercial ELISA kit
57
 from that of 
romosozumab trials. These factors could have contributed to the differences in 
the absolute CTX measurements and in turn account for the differences in the 
change from pre-treatment baseline values.  
 The biomarker responses after anti-sclerostin therapies are interesting. 
Most other available osteoporosis treatments either increase or decrease both 
bone formation and bone resorption
140
. For example, teriparatide increased 
both P1NP and serum type 1 N-terminal procollagen (NTX). The bone 
formation marker, however, increased more than the bone resorption marker, 
resulting in an overall increase in bone mass. Similarly, alendronate decreased 
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both P1NP and NTX and depressed the overall level of bone remodeling 
resulting in a halt in bone loss. Anti-sclerostin treatments, however, 
demonstrated decoupled bone biomarker responses. P1NP levels increased 
rapidly following treatment and then quickly become attenuated; CTX levels, 
on the other hand, decreased initially and then rebounded beyond the 
pretreatment baseline levels; and thereafter fluctuated around the pretreatment 
baseline levels. The decoupled bone formation and bone resorption marker 
responses suggest that in addition to the bone remodeling regulation, sclerostin 
can also affect the bone modeling process. 
Sclerostin and consequently, the wnt signaling pathway, are also 
involved in the bone modeling process. Bone modeling occurs mainly in the 
early growth period, and less throughout the human lifespan, during which the 
bone increases in mass and volume. Bone modeling also sculpts the bone into 
specific three-dimensional form by separating osteoblast and osteoclast actions 
at different bone surfaces (Figure 33). The turnover marker responses based on 
blosozumab and romosozumab suggest that anti-sclerostin therapy could 
possibly affect both the bone modeling and remodeling mechanisms
16,141
. Our 
model currently only describes the bone remodeling process and the 
interaction of the osteoblasts and osteoclasts. The model can be further 
improved to include the bone modeling pathway when more experimental data 






A Bone Modeling         B Bone Remodeling  
 
 
Osteoclast  Osteoblast  New bone matrix 
Note: (A) Bone modeling is the process that accrues bone mass and volume and shapes 
the bone architecture. Bone formation and resorption are decoupled on different 
bone surfaces. (B) Bone remodeling is the process that maintains the bone mass 
and repairs the micro-fractures sustained in mechanical exertion. Bone resorption 
is tightly coupled with subsequent bone formation to maintain bone homeostasis. 
Figure 33 Comparison of (A) bone modeling and (B) bone 
remodeling. 
Another limitation is that the model assumes that the system maintains 
steady state when there is no perturbation to the components. This assumption 
might be appropriate for the duration of a clinical trial when the BMD changes 
over the period of time are not significant. The rate of bone loss as a subject 
ages and estrogen levels changes over time will have to be accounted for if the 
observation period were to be extended. In the population PK-PD model, an 
empirical linear slope of bone loss was added and the estimated linear loss of 
lumbar spine and total hip BMD were 0.0121 g/cm
2
/year and 0.00780 
g/cm
2
/year, respectively (Table 6). This translates to approximately 1-2% 
BMD loss a year (Table 6). A next step towards improving the model will be 
to relate how age and hormonal changes in PMP women affects the bone cell 
interactions and incorporate it into the bone homeostasis model. 
The Metrum group recently reported a similar effort where the action 





approach started with a minimal bone remodeling model and incorporated the 
target-mediated drug disposition of blosozumab and romosozumab with 
unbound sclerostin. The unbound sclerostin then activates or represses the 
specific pathways in the bone remodeling model, based on clinical and pre-
clinical understanding of the sclerostin’s actions at those regulatory junctions. 
The basic structure of bone cell interactions follows that of Lemaire and 
colleagues
6





 and selective estrogen receptor 
modulator
101
. Using similar basic model structure has the advantage that these 
different models can potentially be combined to form a unifying model which 
can then be used to investigate different drug combinations. 
The extended bone remodeling model was built from summary study-
level data that were extracted from reported clinical trials. The model therefore 
lacked the finer resolution of a population PK-PD model, built from patient-
level data that can quantify variability and identify important potential 
covariates that can impact drug exposure and efficacy outcomes. Therefore, 
the strength of the extended bone remodeling model is to screen for a large 
range of dose regimens and evaluate the biomarker and efficacy responses. A 
smaller subset of clinically meaningful dose regimens could then be screened 
and selected. These dose regimens could be further refined and impact of 







8. Summary and Conclusion 
Bone degeneration disease, such as osteoporosis, is an important global 
healthcare issue
144,145
. It is estimated that worldwide, one-third of elderly 
women over 50 years old  suffer from osteoporosis
36
.  In these patients with 
low bone mass, fracture risk increases significantly and these fractures have 
debilitating consequences on the sufferers which include pain, limited physical 
mobility and increased dependence on care-giving services. This healthcare 
issue is expected to grow with an aging population. The standard of care for 
osteoporosis currently is bisphosphonates which is effective but inconvenient 
to administer. Alendronate, for example, needs to be taken weekly on an 
empty stomach while standing or sitting
146
. Then, for the next half an hour, 
patients must stay upright and cannot consume food and water. In addition, 
there are other gastrointestinal side effects that can undermine the quality of 
life and treatment compliance. There are other antiresorptives available, such 
as denosumab, hormone replacement and selective estrogen receptor 
modulators, but concerns that antiresorptive treatments block the overall bone 
turnover and could lead to build-up of micro-fractures in bone architecture 
remain unaddressed. There is only one type of bone anabolic treatment 
available currently, teriparatide, and the use is limited to severe osteoporotic 
patients and limited to a maximum two years’ treatment. Therefore, there is a 
need to develop new bone anabolic treatment for better bone mass accretion, 
with more convenient treatment administration method and better adverse 
event profile. 
Anti-sclerostin therapy is being actively pursued as a treatment for bone 
degenerative disease. This project aimed to utilize a model-based approach in 
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the development of the anti-sclerostin therapy to aid in understanding the 
mechanism of sclerostin action on bone formation activities as well as propose 
clinically meaningful dose regimens that can improve clinical outcomes.  
In the first part, population PK-PD modeling was developed for 
blosozumab to integrate the vast clinical data collected in three phase 1 trials 
and one phase 2 trial. Model-based dose selection approach eliminates “best-
guessing” untested dose regimens for future trials. Simulations based on the 
validated PK-PD model were performed to investigate drug exposures and 
dose response in a panel of different dose regimens. Different dosing 
frequencies that were not tested in previous trials were investigated. BMD 
responses in lumbar spine and total hip were simulated and the results 
suggested that 135mg Q1W, 270mg Q2W and 540mg Q1M frequencies were 
comparable in terms of their efficacy responses and could be investigated in 
future clinical trials. Nevertheless, the dose regimens will need to balance 
efficacy with the ease of administration to improve drug compliance and also 
to take safety and tolerability into consideration. Poor patient compliance was 
cited as the main reason for the poor outcome of fracture incidences in current 
available osteoporosis treatments in real world setting. The incidence of 
fractures in clinical observations were much higher compared to randomized 
controlled trials
147
. A convenient dosing regimen with fewer restrictions on 
intake instructions can potentially offer greater benefits to patients in the real 
world. Anti-sclerostin mAbs that are administered as SC injections without 
other dietary limitations and have a longer dosing interval offers exciting 
possibilities to fill this gap in current available osteoporosis treatments.  
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We demonstrated the use of PK-PD modeling by combining knowledge of 
blosozumab’s properties accrued over the four clinical studies exploring a 
wide range of doses, including IV and SC injections, and making predictions 
for potential effective dose regimens for phase 3 clinical investigations. We 
built a PK model that described the nonlinear kinetics in blosozumab and 
linked it to the lumbar spine and total hip BMD response. Because of the non-
linear kinetics displayed in the drug, dose proportionality is not guaranteed 
whereby a doubling of dose results in a doubling of exposure. Using the PK 
model, we were able to simulate and compare drug exposures in different dose 
regimens, within the drug exposure that was tested clinically, and make 
informed decisions about the exposure-response outcomes by maximizing the 
BMD response while minimizing the variability. Many late-phase clinical 
trials fail because of ineffective dosage and regimen. Doses that are too high 
expose subjects to higher risk of adverse events while doses that are too low 
might be safe but ineffective. Appropriate dose selection for late-phase trial is 
crucial so that effective drugs can be thoroughly investigated with greater 
probability of success.  
The second part of this project combined the publicly available 
information on clinical uses of anti-sclerostin therapies, blosozumab and 
romosozumab, to extend a systems model of bone remodeling and add 
sclerostin regulation of bone cell interaction. Bone turnover biomarkers and 
BMD were incorporated into the model and the simulations of the biomarkers 
and BMD emulate the observations in anti-sclerostin mAbs clinical trials. The 
model predictions of different clinically meaningful dosing regimens were 
consistent with the population PK-PD model and dosing frequencies of Q1W, 
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Q2W and QM were predicted to yield similar favorable BMD responses. 
Simulation experiments were performed to explore the effects of sclerostin 
regulation and predict the duration of the bone system to attain steady state, 
the duration of preosteoblast recovery and the duration of treatment effect 
washout. Such probing of the system, which is difficult to be performed 
clinically, but can be done readily in silico using our model, will be useful to 
map the characteristics of anti-sclerostin therapy and guide future 
investigations.  
Our effort adds to the knowledge of the different mechanisms of bone 
formation and resorption regulation. Parameterization of the model with the 
basic bone remodeling model that other research groups worked on will also 
facilitate the future integration of the different drug models to form a unified 
model.  The unified model can integrate various sources of knowledge and 
potentially be used to address questions about combination therapies where 
adding different drug treatment does not equal to a simple arithmetic addition 
of drug effects. For example, one might consider adding a combination of 
antiresorptive drug and anabolic drug to boost the BMD increase by targeting 
the two pathways of bone balance. However, adding bisphosphonate to 
teriparatide treatment did not result in better clinically significant BMD 
response
148
  and in some cases, the combination therapy fared worse than the 
using teriparatide alone
83
. Prior bisphosphonate treatment also attenuated the 
BMD response in teriparatide treatment
149,150
. On the other hand, using 
denosumab and teriparatide together demonstrated better BMD responses than 
using either drug alone
151,152
. These suggest that the simpler reasoning of 
inhibiting bone resorption and stimulating bone formation without considering 
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the underlying mechanism of action will not be sufficient to help clinicians 
make decisions for better patient care. A unified bone systems biology model 
will allow us to investigate combination therapies in virtual population, based 
on knowledge and complexities of bone cell feedback and signaling loops that 
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Appendix A  
10.1. Equations for the Extended Bone Remodeling model 
 
The full set of equations and governing the kinetics of anti-sclerostin 
drug, sclerostin and bone remodeling activities are presented here: 
The kinetics of serum sclerostin after anti-sclerostin treatment is 
represented by equations A1 to A4. The mechanics of bone remodeling 
involving osteoblasts and osteoclasts interactions and sclerostin regulation 
added are represented by equations A5 to A7. 




= −𝑘𝑎 ∙ 𝐴𝑠.𝑐. + 𝐷𝑜𝑠𝑒𝑠.𝑐. A1 
𝑑(𝐶𝑡𝑜𝑡𝑎𝑙)
𝑑𝑡
= 𝐼𝑛(𝑡) + 𝑘𝑎 ∙
𝐴𝑠.𝑐.
𝑉
− (𝑘 + 𝑘23) ∙ 𝐶𝑠𝑒𝑟𝑢𝑚 +  𝑘32 ∙
𝐴𝑡
𝑉






= 𝑘23 ∙ 𝐶 ∙ 𝑉 − 𝑘32 ∙ 𝐴𝑡 A3 
𝑑(𝑆𝑐𝑙𝑡𝑜𝑡𝑎𝑙)
𝑑𝑡






= 𝐷𝑅 ∙ 𝜋𝐶 − 𝜋𝑆𝑅 ∙  
𝐷𝐵
𝜋𝐶






∙ 𝑅𝑂𝐵 − 𝑘𝐵 ∙ 𝜋𝑆𝐵 ∙ 𝐴𝑂𝐵 A6 
𝑑(𝐴𝑂𝐶)
𝑑𝑡
= 𝐷𝐶 ∙ 𝜋𝐿 −  𝐷𝐴 ∙ 𝜋𝐶 ∙ 𝐴𝑂𝐶 A7 
𝑑(𝐸𝑓𝑓𝑒𝑐𝑡𝐿𝑆)
𝑑𝑡
= 𝑘𝑒0,𝐿𝑆𝐵𝑀𝐷 ∙  (𝐴𝑂𝐵 − 𝐸𝑓𝑓𝑒𝑐𝑡𝐿𝑆) A8 
𝑑(𝐿𝑆𝐵𝑀𝐷)
𝑑𝑡





− 𝑘𝑜𝑢𝑡𝐵𝑀𝐷 ∙ 𝐿𝑆𝐵𝑀𝐷 A9 
𝑑(𝐸𝑓𝑓𝑒𝑐𝑡𝐻𝐼𝑃)
𝑑𝑡
= 𝑘𝑒0𝐻𝐼𝑃𝐵𝑀𝐷 ∙  (𝐴𝑂𝐵 − 𝐸𝑓𝑓𝑒𝑐𝑡𝐻𝐼𝑃) A10 
𝑑(𝐻𝐼𝑃𝐵𝑀𝐷)
𝑑𝑡





− 𝑘𝑜𝑢𝑡𝐿𝑆𝐵𝑀𝐷 ∙ 𝐻𝐼𝑃𝐵𝑀𝐷 A11 
where  




∙ 𝐴𝑂𝐶𝑠𝑠 A13 
 𝑘𝑜𝑢𝑡𝐿𝑆𝐵𝑀𝐷 = 𝑘𝑖𝑛𝐻𝐼𝑃𝐵𝑀𝐷  A14 




















































(𝐶𝑡𝑜𝑡𝑎𝑙 − 𝑆𝑐𝑙𝑡𝑜𝑡𝑎𝑙 − 𝐾𝐷) + √(𝐶𝑡𝑜𝑡𝑎𝑙 − 𝑆𝑐𝑙𝑡𝑜𝑡𝑎𝑙 − 𝐾𝐷)2 + 4 × 𝐾𝐷 ∙ 𝐶𝑡𝑜𝑡𝑎𝑙
2
 A23 






𝑅𝐴𝑁𝐾𝐿 = 𝜋𝑆𝐿 ×




























Table 16 Initial Conditions for Differential Equations A1 to A7  
Symbol Description Value 
𝐴𝑠.𝑐. 


























𝐴𝑂𝐶 active osteoclast 9.127 x 10-4 pMb 
𝐸𝑓𝑓𝑒𝑐𝑡𝐿𝑆 
transit compartment for osteoblast action on 




𝐿𝑆𝐵𝑀𝐷 lumbar spine BMD 1 
𝐸𝑓𝑓𝑒𝑐𝑡𝐻𝐼𝑃 
transit compartment for osteoblast action on 




𝐻𝐼𝑃𝐵𝑀𝐷 total hip BMD 1 
a 
fixed to average baseline value of sclerostin measurement from blosozumab studies        
b 







Appendix B  
10.2. Derivation of the Quasi-Equilibrium Target-Mediated 
Drug Disposition for Anti-Sclerostin Therapy and 
Unbound Sclerostin 
 
Target-mediated drug disposition can be described with a system of 
five differential equations (B1 to B5) based on mass balance of unbound drug 
in site of administration and serum, unbound drug in tissue, unbound target in 











= 𝐼𝑛(𝑡) + 𝑘𝑎 ∙ 𝐴𝑠.𝑐. − (𝑘 + 𝑘23) ∙ 𝐶 ∙ 𝑉 + 𝑘32 ∙ 𝐴𝑡 − 𝑘𝑜𝑛 ∙ 𝐶 ∙ 𝑉 ∙ 𝑆𝑐𝑙 + 𝑘𝑜𝑓𝑓




= 𝑘23 ∙ 𝐶 ∙ 𝑉 − 𝑘32 ∙ 𝐴𝑡 B3 
𝑑(𝑆𝑐𝑙)
𝑑𝑡
= 𝑘𝑠𝑦𝑛 − 𝑘𝑑𝑒𝑔 ∙ 𝑆𝑐𝑙 − 𝑘𝑜𝑛 ∙ 𝐶 ∙ 𝑆𝑐𝑙 + 𝑘𝑜𝑓𝑓 ∙ 𝐶𝑝𝑙𝑥 B4 
𝑑(𝐶𝑝𝑙𝑥)
𝑑𝑡
= 𝑘𝑜𝑛 ∙ 𝐶 ∙ 𝑆𝑐𝑙 − (𝑘𝑜𝑓𝑓 + 𝑘𝑖𝑛𝑡) ∙ 𝐶𝑝𝑙𝑥 B5 
  
The binding and unbinding of drug to the unbound sclerostin occurs at 
a much rapid rate compared to the serum kinetics of the drug and unbound 
sclerostin such that the binding process could be considered to be in a quasi-
equilibrium state and the binding and unbinding constants (𝑘𝑜𝑛 𝑎𝑛𝑑 𝑘𝑜𝑓𝑓)  were 
replaced by a dissociation constant (𝐾𝐷). The total sclerostin is the sum of 
unbound sclerostin and the drug-sclerostin complex and therefore  𝑆𝑐𝑙 =






















For subsequent manipulation, equation B2 was first changed from 
amount of drug to concentration of drug in the serum by dividing both sides of 
the equation by 𝑉. 
𝑑(𝐶)
𝑑𝑡
= 𝐼𝑛(𝑡) + 𝑘𝑎 ∙
𝐴𝑠.𝑐.
𝑉
− (𝑘 + 𝑘23) ∙ 𝐶 + 𝑘32 ∙
𝐴𝑡
𝑉
− 𝑘𝑜𝑛 ∙ 𝐶 ∙ 𝑆𝑐𝑙 + 𝑘𝑜𝑓𝑓 ∙ 𝐶𝑝𝑙𝑥 
B7 
  
Serum drug and drug complex concentration can be simplified to total 
drug concentration by adding equations B7 and B5. 
𝑑(𝐶 + 𝐶𝑝𝑙𝑥)
𝑑𝑡
= 𝐼𝑛(𝑡) + 𝑘𝑎 ∙
𝐴𝑠.𝑐.
𝑉
− (𝑘 + 𝑘23) ∙ 𝐶 + 𝑘32 ∙
𝐴𝑡
𝑉




= 𝐼𝑛(𝑡) + 𝑘𝑎 ∙
𝐴𝑠.𝑐.
𝑉













Similarly, serum unbound sclerostin and drug complex concentration 
























The serum drug concentration can be solved with the total drug 
concentration and the total sclerostin concentration in the quadratic equation 
B10. 
𝐶 = 𝐶𝑡𝑜𝑡𝑎𝑙 −  𝐶𝑝𝑙𝑥  





𝐶2 − (𝐶𝑡𝑜𝑡𝑎𝑙 − 𝑆𝑐𝑙𝑡𝑜𝑡𝑎𝑙 − 𝐾𝐷) ∙ 𝐶𝑠𝑒𝑟𝑢𝑚 − 𝐾𝐷 ∙ 𝐶𝑡𝑜𝑡𝑎𝑙  
𝐶 =









In summary, the quasi-steady state target-mediated drug disposition 
model is described by equations B1, B8, B3, B9 and B10. 
𝑑(𝐴𝑠.𝑐.)
𝑑𝑡




= 𝐼𝑛(𝑡) + 𝑘𝑎 ∙
𝐴𝑠.𝑐.
𝑉






























Appendix C  
10.3. Derivation of RANK-RANK-OPG regulation (𝝅𝑳) in Bone 
Remodeling Model as Described by Lemaire et al, 2004. 
 
 
For the complete discussion, assumptions and derivation of the 
RANKL-RANK-OPG regulation (𝜋𝐿), reader is referred to the original bone 
remodeling model publication by Lemaire and colleagues (2004)
6
.  
A simplified discussion on the important aspects of the RANKL-
RANK-OPG regulation is reproduced here to improve the understanding of 
the bone remodeling model. 
The kinetics of RANKL (L), OPG (O), RANK (K), OPG-RANKL 
complex (OL) and RANK-RANKL (KL) complex are described in equations 








 Note that the concentration of RANK was fixed, based on the 
assumption that the osteoclast precursors (where RANK is expressed as a 




= 𝑝𝑂 − 𝑘1 ∙ 𝑂 ∙ 𝐿 + 𝑘2 ∙ 𝑂𝐿 − 𝑑𝑂   C1 
𝑑(𝐿)
𝑑𝑡
= 𝑝𝐿 − 𝑘1 ∙ 𝑂 ∙ 𝐿 + 𝑘2 ∙ 𝑂𝐿 − 𝑘3 ∙ 𝐾 ∙ 𝐿 + 𝑘4 ∙ 𝐾𝐿 − 𝑑𝑂 C2 
𝑑(𝑂𝐿)
𝑑𝑡
= 𝑘1 ∙ 𝑂 ∙ 𝐿 + 𝑘2 ∙ 𝑂𝐿 C3 
𝑑(𝐾𝐿)
𝑑𝑡




The production of OPG was assumed to be a first order reaction and 
depended on the concentration of ROB and the intrinsic rate of OPG 
production (𝐾𝑃𝑂 ) by 𝐾𝑃𝑂 × 𝑅𝑂𝐵 .  Additionally, PTH inhibits the OPG 
production and this was implemented by an inverse relationship with PTH 
occupancy (𝜋𝑃) by 𝑝𝑂 ≈
1
𝜋𝑃




∙ 𝑅𝑂𝐵 C5 
  
The production of RANKL was more complex as it is an osteoblast 
surface molecule and therefore RANKL concentration was limited by the 
number and surface carrying capacity of osteoblasts. The process involving 
RANKL production is described in equation C6. To restrict the RANKL 
production, RANKL turnover (𝑝𝐿 − 𝑑𝐿) was limited such that production rate 
of RANKL (𝑝𝐿) was proportional to and not exceed the ratio of total RANKL 
concentration (𝐿 + 𝑂𝐿 + 𝐾𝐿) and the maximum surface carrying capacity of 
osteoblasts (𝐾𝑃𝐿 ∙ 𝐴𝑂𝐵) by 
𝐿+𝑂𝐿+𝐾𝐿
𝐾𝑃𝐿×𝐴𝑂𝐵
. 𝐾𝑃𝐿 represents the maximum number of 
RANKL molecule per osteoblast. Additionally, PTH up-regulates RANKL 
production and this was implemented by 𝐾𝑃𝐿 × 𝜋𝑃 × 𝐴𝑂𝐵, where increasing 








𝑝𝐿 − 𝑑𝐿 = 𝑝𝐿 ∙ (1 −
𝐿 + 𝑂𝐿 + 𝐾𝐿
𝐾𝑃𝐿 ∙ 𝜋𝑃 ∙ 𝐴𝑂𝐵
) C6 
  
Note that the level of PTH was kept constant in our analysis and 𝜋𝑃 did 




 By evaluating equations C1 to C6 at steady state, the steady state 
concentration of RANKL and OPG can be derived as per equation C7 and C8.  
𝐿 =















The RANK-RANKL-OPG axis of osteoblast-osteoclast interaction 
(𝜋𝐿) (Equation C9), based on receptor occupancy of RANK-RANKL, was 
evaluated at steady state since it was assumed that the binding reaction was 
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STARTTIME = 0 
STOPTIME=  2*365*24 + 782  ; Enter the time of last observation in hours (e.g., 1 
year =  8736 hours) 
DT = 0.1;0.02 
DTOUT = 0.1 
 
 
;-----  Define the Blosozumab regimens -----;  
Dose    =   270  ; Enter dose in mg (e.g., 270mg) 
Dose_Interval = 336 ; Enter dosing interval in hours (e.g., 2 weeks = 336 hours) 
Dose_End  = 8736 ; Enter the time of last dose in hours (e.g., 1 year =  8736 hours) 
Dose_Route = 1 ; Enter the administration route  
  (i.e., 1 = subcutaneous, 2 = intravenous) 
 
 
; Set up dose according to the dosing options 
DD1   =  Dose*1E6/150 * (pulse(1,0,Dose_Interval) - 
pulse(1,Dose_End+Dose_Interval,Dose_Interval)) 
DSC1 = IF Dose_Route = 1 THEN DD1*FM ELSE 0 
DIV1   = IF Dose_Route = 2 THEN DD1 ELSE 0 
 
;----- initial estimates -----;  
R0 = (DR*Pic0^2)/(DB*PiSr0) ;pM - baseline ROB (Responding Osteoblast) 
B0 = (DR*Pic0)/(kB*PiSb0) ;pM - baseline AOB (Active Osteoblast) 
C0 = 9.127e-4   ;pM - baseline AOC (Active Osteoclast) 
PTH0 = 3.6*14   ;pmol - baseline PTH amount 
PTHConc0 = 3.6  ;pM - baseline PTH concentration 
RANK0 =10   ;pmol - baseline RANK 
LSBMD0 = 1   ;nil - baseline Lumbar Spine BMD 
HPBMD0 = 1   ;nil - baselineTotal Hip BMD 
 
;--------- Parameter estimates ---------;  
 
; cellular interaction 
Cs = 0.005   ;pM - value of C to get half differentiation flux 
DA = 0.0533046  ;1/h  - rate of osteoclast apoptosis caused by TGF-b 
dsB =0.01*0.7/24  ;1/h  - differentiation of responding osteoblast 
DC = DA*Pic0*C0/(PiL0)  ;pM/h  - differentiation rate of osteoclast precursor 
DR = 2.91667E-6  ;pM/h  - differentiation rate of osteoblast progenitors 
f0 = 0.05   ;nil - fixed proportion 
IL = 0    ;pM/h - rate of administration of RANKL 
IO = 0    ;pM/h - rate of administration of OPG 
Ip = 0    ;pM/h - rate of administration of PTH 
RANK = 10   ;pM - fixed concentration of RANK 
k1 = 0.01/24   ;1/pM/h - rate of OPG-RANKL binding 
k2 = 10/24   ;1/h - rate of OPG-RANKL unbinding 
k3 = 0.00058/24  ;1/pM/h - rate of RANK-RANKL binding 
k4 = 0.017/24   ;1/h - rate of RANK-RANKL unbinding 
k5 = 0.02/24   ;1/pM/h - rate of PTH binding with its receptor 
k6 = 3/24   ;1/h - rate of PTH unbinding 




KPL = 3E6   ;pmol/pmol cell - maximum number of RANKL  
  attached on each cell surface 
kO = 0.35/24   ;1/h - rate of elimination of OPG 
KPO = 2E5/24   ;pmol/day/pmol cell - minimal rate of production  
  of OPG per cell 
kp = 86/24   ;1/h - rate of elimination of PTH 
rL = 1000/24   ;pM/h - rate of RANKL production and elimination 
Sp = kp*PTH0   ;pM/h - rate of synthesis of systemic PTH 
f0s = 0.431421   ;nil - proportionaility constant 
 
; blosozumab-sclerostin 
V1 = 2520    ;ml -  blosozumab Central Volume of Distribution 
CL  = 8.82    ;ml/h -  blosozumab Clearance   
V2 = 1440     ;ml -  blosozumab peripheral Volume of  
   Distribution   
KA = 0.00697    ;1/h -  blosozumab rate of absorption 
Q = 16.8      ;ml/h -  blosozumab intercompartmental clearance 
FM = 0.691     ;fraction -  blosozumab absolute bioavailability 
KSYN =KDEG*Scl0  ;pmol/h -  rate of sclerostin production 
KDEG =1.5313   ;1/h -  rate of sclerostin elimination   
KINT = 0.0272139   ;pmol/h -  rate of drug-sclerostin complex elimination
   
KSS =0.36164   ;pmol/h -  rate of drug-sclerostin complex elimination 
Scl0 = 0.2594   ;nM - baseline unbound sclerostin level 
 
; sclerostin effect on bone remodeling 
EmaxPiSr =10.9085  ;nil  - maximum effect of sclerostin on osteoblast  
   maturation 
Sc50r =  0.198425  ;pmol/ml - potency of sclerostin on osteoblast  
    maturation 
EmaxPiSb = 5.13131  ;nil  - maximum effect of sclerostin on osteoblast  
    apoptosis 
Sc50b = 0.0153283  ;pmol/ml - potency of sclerostin on osteoblast  
    apoptosis 
EmaxPiSL = 1.77016  ;nil  - maximum effect of sclerostin RANKL level 
Sc50L =0.0691952  ;pmol/ml- potency of sclerostin on RANKL level 
EmaxPiSO =1.80461  ;nil  - maximum effect of sclerostin OPG level 
Sc50O = 0.0179259  ;pmol/ml- potency of sclerostin on OPG level 
 
; BMD  
kinLSBMD = 0.0769255  ;1/h - lumbar spine BMD production rate 
kinHPBMD = 0.0714122 ;1/h - total hip BMD production rate 
KDELAY1= 7.18514e-5   ;1/h - transduction rate of AOB effect on lumbar  
  spine BMD  
KDELAY2= 2.82831e-5  ;1/h - transduction rate of AOB effect on total hip  
   BMD  
kinLSBMDgam = 0.495861 ;1/h - exponent of AOB effect on lumbar spine  
   BMD  
koutLSBMDgam = 0.191044 ;1/h - exponent of AOC effect on lumbar spine  
   BMD 
kinHPBMDgam = 0.451389 ;1/h - exponent of AOB effect on total hip BMD 





PiLS1=(k3/k4) *PiSLS1 * (1+IL/rL) * (KPL*PiP*BS1) / (1 +(k1/k2)*OS1 + (k3/k4)*RANK)
  
LS1 =  (KPL*PiP*BS1) / (1 + (k3*RANK/k4) + (k1*OS1/k2))*PiSLS1 




K20 = CL/V1 
K23 = Q/V1 
K32 = Q/V2 
 
PiSrS1 = EmaxPiSr/(1+(SCLS1/Sc50r)) 
PiSbS1 = 1+EmaxPiSb*SCLS1/(SCLS1+Sc50b) 
PiSLS1 = 1+EmaxPiSL*SCLS1/(SCLS1+Sc50L) 
PiSOS1 = EmaxPiSO/(1+(SCLS1/Sc50O)) 
 
 
koutLSBMD = kinLSBMD/LSBMD0/168 
koutHPBMD = kinHPBMD/HPBMD0/168 
 
BeffLSBMDS1 = (TR1S1/B0)^kinLSBMDgam 
CeffLSBMDS1 = (CS1/C0)^koutLSBMDgam 
BeffHPBMDS1 = (TR2S1/B0)^kinHPBMDgam 
CeffHPBMDS1 = (CS1/C0)^koutHPBMDgam 
 
;----- steady state computation -----;  
PiC0 = (C0+f0*Cs)/(C0+Cs) 
PiL0 =(k3/k4) * PiSL0 * (KPL*PiP0*B0) / (1 +(k1/k2)*OPG0 + (k3/k4)*RANK0)  
PiP0 = (Pd + P0)/(Pd + Ps)  
RANKL0 =  (KPL*PiP0*B0) / (1 + (k3*RANK0/k4) + (k1*OPG0/k2))*PiSL0 
OPG0 = (KPO*R0/(kO*PiP0)) * PiSO0 
 
PiSr0 = EmaxPiSr/(1+(Scl0/Sc50r)) 
PiSb0 = 1+EmaxPiSb*Scl0/(Scl0+Sc50b) 
PiSL0 = 1+EmaxPiSL*Scl0/(Scl0+Sc50L) 
PiSO0 = EmaxPiSO/(1+(Scl0/Sc50O)) 
 
 
;----- derived parameters computation -----;  
  
PiP = (Pd + P0)/(Pd + Ps)  
Pd = Ip/kp 
P0 = Sp/kp 
Ps = k6/k5 
 
;----- differential equations -----;  
 
d/dt(PTH) = Sp - kp*PTH  
INIT PTH = PTH0 
d/dt(X1S1) =-KA*X1S1 + DSC1 
INIT X1S1 = 0 
d/dt(X2S1) = KA*X1S1-(K20+K23)*CPS1*V1+K32*X3S1-
KINT*X4S1*CPS1*V1/(KSS+CPS1) + DIV1 
INIT X2S1 = 0     
d/dt(X3S1) = K23 *CPS1*V1-K32*X3S1 
INIT X3S1 = 0 
d/dt(X4S1) = (KSYN) - KDEG*X4S1 + (KDEG-KINT)*X4S1*CPS1/(KSS+CPS1)  
INIT X4S1 = Scl0 
d/dt(RS1) = DR*PicS1 - DB*RS1*PiSrS1/(PicS1)  
INIT RS1 = R0 
d/dt(BS1) = DB*RS1*PiSrS1/(PicS1) - kB*PiSbS1*BS1 
INIT BS1 = B0 
d/dt(CS1) = DC*PiLS1 - DA*PicS1*CS1 
INIT CS1 = C0  
d/dt(TR1S1) = KDELAY1*(BS1 - TR1S1) 
INIT TR1S1 = B0 
 168 
 
d/dt(LSBMDS1) = (kinLSBMD/168)*BeffLSBMDS1 - koutLSBMD*CeffLSBMDS1* 
LSBMDS1 
INIT LSBMDS1 = LSBMD0 
d/dt(TR2S1) = KDELAY2*(BS1 - TR2S1) 
INIT TR2S1 = B0 
d/dt(HPBMDS1) = (kinHPBMD/168)*BeffHPBMDS1 - koutHPBMD*CeffHPBMDS1* 
HPBMDS1 
INIT HPBMDS1 = HPBMD0 
 
 
;----- for plotting purposes -----;  
 
PTHConc = PTH/14       
DAY = TIME/24 
WEEK = TIME/168 
MONTH = TIME/((13/3)*168) 
 
TCPS1 =  X2S1/V1     ; Total drug concentration 
CPS1 =  (0.5*(X2S1/V1-X4S1-KSS)+0.5*SQRT((X2S1/V1-X4S1-
KSS)^2+4*KSS*X2S1/V1))   ; Unbound drug concentration 
TSCLS1 = X4S1    ; Total sclerostin concentration 
SCLS1 = TSCLS1 - CPLXS1    ; Unbound sclerostin concentration 
CPLXS1 =  TSCLS1*CPS1/(KSS+CPS1)  ; Drug-sclerostin complex concentration 
P1NPS1_PCFB = (BS1/B0-1)*100  ; Percent change in P1NP 
CTXS1_PCFB = (CS1/C0-1)*100  ; percent change in CTX 
TSCLS1_PCFB = (TSCLS1/Scl0-1)*100  ; percent change in total sclerostin 
SCLS1_PCFB = (SCLS1/Scl0-1)*100  ; percent change in unbound sclerostin 
LSBMDS1_PCFB = (LSBMDS1/LSBMD0-1)*100 ; percent change in lumbar spine BMD 
HPBMDS1_PCFB = (HPBMDS1/HPBMD0-1)*100 ; percent change in total hip BMD 
 
 
 
